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The genes of the human 0-globin locus are located on chromosome 11 in the order 
of their expression during development: 5' E ,  y, 0 3'. During development, silencing of 
the 5' gene occurs with activation of the immediate 3' gene. This process occurs twice 
and is termed hemoglobin switching. The exact mechanism(s) of this process have not 
been fully described. Herein, we describe a role for DNA methylation and methyl binding 
domain protein 2 in the transcriptional regulation of the human embryonic and fetal beta 
type globin genes. Adult mice containing the entire human 0-globin locus as a yeast 
artificial chromosome ( P A C )  express very low levels of the fetal y-globin gene. 
However, treatment of adult OYAC transgenic mice with the DNA methyltransferase 
inhibitor, 5-azacytidine, induces a >lo-fold increase y-globin mRNA levels. In addition, 
. . . 
X l l l  
PYAC transgenic mice null for methyl binding domain protein 2 (MBD2) express a 
similar level of y-globin niRNA. DNA niethylation and MBD2 appear to induce y-globin 
expression via the same pathway(s), as treatment of MBD2 null PYAC transgenic mice 
do not show an additive boost in y-globin expression. MBD2 does not bind to the y- 
globin promoter region in vivo indicating MBD2 mediated transcriptional silencing does 
not occur by recruitment of transcriptional repression complexes to the y-globin gene 
promoter. Additionally, these transgenic mice contain only the 5' portion of the 0-globin 
locus through the c-globin, and do not express the c-globin genes as adults. However, 
treatment with 5-azacytidine or loss of MBD2 induces expression of the c-globin gene in 
adult transgenic mice. A similar induction of c-globin is seen in PYAC transgenic mice 
under the same conditions. The level of expression of the c-globin gene is much lower 
than the y-globin gene, indicating the powerful effect of the cis elements mediating 
transcriptional repression of the c-globin gene. These studies indicate DNA methylation 
and MBD2 contribute to the transcriptional repression of the human embryonic and fetal 
@-type globin genes. Additionally, MBD2 has been identified as a potential target for the 
therapeutic induction of fetal hemoglobin for the treatment of henioglobinopathies. 
Chapter 1 : Introduction 
The Human P-globin Locus 
The human P-globin locus is located on chromosome 11 and the genes of the 
locus encode the 0 chain of hemoglobin. The genes are positioned in the order of their 
expressioii during development: 5' E ,  y, 6, and 3' (Figure 1 and 2). Two switches in 
globin gene expression occur during development. The first occurs during the switch 
from embryonic (primitive) to definitive hematopoiesis at 5 weeks post-conception. At 
this time, y-globin replaces €-globin as the major 0-chain subunit. This time also marks a 
change in the site of hematopoiesis from the yolk sac to the fetal liver. At the time of 
birth, the second switch takes place whereby 0-globin replaces y-globin. By birth, the 
bone marrow has become the primary site of hematopoiesis. 
High level globin gene expression at all stages of development is regulated at 
least in part by the locus control region (LCR). The LCR acts as an enhancer, resides 6- 
20 kb upstream of the €-globin gene, and consists of five DNase I hypersensitive sites 
(HS1-5) (Stamatoyannopoulos and Grosveld, 2001). In addition, it confers copy-number 
LCR 
5 4 3 2 1  
Human P-globin locus 
Murine P-globin locus 
Figure 1 : The human and murine P-globin loci. The top picture depicts the human P- 
globin locus while .the bottom depicts the murine P-globin locus. Numbers and arrows 
indicate the position of DNase I hypersensititve sites wi.thin the locus control region 
(LCR). The black boxes are the positions of the genes within each locus. 
Figure 2: 6-type globin chain switching during development. This graph depicts the 
switch in expression of 6-type globin genes during development (Harju et al., 2002). 
dependent position-independent expression of a linked gene in transgenic mice (Fraser 
and Grosveld, 1998; Grosveld et al., 1987). 
The mouse has been a useful model system for the study of globin gene 
regulation. In mice, the first switch in globin gene expression takes place at day 10.5 
post-conception, when erythropoiesis shifts from the yolk sac to the fetal liver (Chada et 
al., 1986; Farace et al., 1984). The mouse yolk sac contains erythroblasts of primitive 
hematopoiesis and expresses the ~y (orthologous to the human E) and phl (orthologous to 
the human y) globin genes. Unlike its orthologue, phl is only expressed in the cells of 
primitive hematopoiesis. The fetal liver is the site of definitive hematopoiesis and 
contains erythroblasts expressing the adult globin genes &major and 0-minor. Unlike the 
human locus, the genes of the mouse 0-globin locus are not expressed in the order of their 
position on the chromosome with phl expression coming first, followed by ~y expression 
(Kingsley et al., 2005). However, mouse 0-type globin genes undergo a similar switching 
program as is seen during human development (Figure 3). Interestingly, mice lack a fetal 
&type globin gene as neither the ~y gene nor the phl gene is expressed in the fetal liver. 
Nevertheless, due to evolutionary conservation, the mouse allows for the study of human 
globin gene switching. Transgenic mice containing 70 to 248 kb constructs of the entire 
human @-globin locus as ligated cosmids, yeast artificial chromosomes (YACs), bacterial 
artificial chromosomes (BACs), and phage artificial chromosomes (PACs) show correct 
temporal expression patterns of the human genes during mouse development (Gaensler et 
al., 1993; Imam et al., 2000; Peterson et al., 1993a; Peterson et al., 1993b; Peterson et al., 
1997; Peterson et al., 1998; Porcu et al., 1997; Strouboulis et al., 1992) (Figure 3). These 
Days 
Figure 3: Endogenous and human @-type globin switching in whole locus transgenic 
mice. This graph depicts the changes in 6-type globin gene expression during 
development. The y-axis on the left half depicts the level of human @-globin expression 
in transgenic mice containing the entire human P-globin locus as a yeast artificial 
chromosome during development. The y-axis on the right depicts the level of 
endogenous mouse 6-type globin expression during development (Gaensler et al., 1993). 
transgenic mice express the fetal y-globin gene in the fetal liver, but it is not expressed as 
highly as the human P-globin gene. The €-globin gene is expressed solely in the yolk sac 
during primitive erythropoiesis. Expression of the y-globin gene begins in the yolk sac 
during primitive erythropoiesis and continues into the definitive cells of the fetal liver, 
finally switching off around day 17. Expression of the 0-globin gene begins at day 12 in 
the fetal liver and is the only gene expressed in the adult. The ability of the mouse to 
correctly regulate human P-globin transgenes has had a profoulid impact upon the study 
of globin gene regulation. Through mutation, truncation, and rearrangement, insight has 
been gained on the impact of cis regulatory elements within the P-globin locus. In 
addition, the effects of gene overexpression or gene knock-out on globin gene regulation 
have been studied. 
Globin Gene Regulation 
The globin genes each consist of three exons and two introns. Tissue specific 
developmental regulation is achieved through the interaction of transcription factors and 
regulatory elements flanking each gene and elements located at a distance from the genes. 
~ r a n s ~ e n i c  mice derived from two different human €-globin constructs express .the gene 
during primitive erythropoiesis, but fail to express upon definitive erythropoiesis (Raich 
et a]., 1990; Shih et al., 1990). Thus, all elements necessary for developmentally correct 
expression and silencing of €-globin gene silencing are located within the constructs used 
in these studies, a mechanism termed autonomous silencing. The mechanism for y-globin 
gene silencing differs slightly, as it is regulated partially by autonomous silencing and 
partially by competition with other globin genes for upstream enhancer activity. When 
attached to the LCR in the context of a transgenic mouse, y-globin mRNA is highly 
expressed during the embryonic and fetal stages of development and is silenced in adult 
mice. However, detectable levels of y-globin mRNA are seen in adult mice (Behringer et 
al., 1990; Enver et al., 1989; Enver et al., 1990). When linked to a P-globin construct, the 
y-globin gene becomes completely silenced in adult transgenic mice (Behringer et al., 
1990; Enver et al., 1990). Thus the y-globin gene is not completely silenced 
autonomously and is dependent upon competition with other downstream globin genes 
for complete silencing. 
Specific cis elements have been investigated for their role in the autonomous 
silencing of the e-globin gene. The first element discovered was located between -177 
and -392 bp relative to the mRNA initiation site using a transfection assay (Cao et al., 
1989). Deletion of a region between -1 82 and -467, relative to the transcription start site, 
in transgenic mice corroborated this finding (Raich et al., 1992). The region includes 
three binding sites important for silencing: a GATA site at -208, a YY 1 site at -269, and a 
CACCC motif at -379 (Peters et al., 1993; Raich et al., 1995). Interestingly, the GATA 
site seems to act as a silencing motif. Disruption of the GATA site at -208 leads to e- 
globin expression in adult transgenic mice (Raich et al., 1995). Furthermore, 
overexpression of GATA-1 in K562 cells and transgenic mice leads to €-globin 
suppression (Ikonomi et al., 2000; Li et al., 1997). Mutations of the YY 1 site and 
CACCC element lead to low levels of e-globin in adult transgenic mice (Raich et al., 
1995). The -182 to -467 silencer was studied using a 2.5kb micro-LCR and a 3.7 kb 
EcoRI fragment of the e-globin gene (Raich et al., 1992). Different results were seen 
upon deleting a fragment from -179 to -304 in the context of a yeast artificial 
chromosome (Liu et al., 1997). The deletion included the YY 1 and GATA binding sites 
previously defined as silencing elements. Transgenic mice harboring the YAC deletion 
construct failed to express e-globin during primitive erythropoiesis and displayed reduced 
y-globin expression at the same time (Liu et al., 1997). These data indicate the region 
may act as an activator during development. This work shows the importance of using the 
complete globin locus to study the autonomous silencing of the e-globin gene, and, in 
addition, that other silencing elements may be present. In fact, two inverted direct repeats 
of a short motif analogous to DR-1 binding sites for non-steroid nuclear hormone 
receptors located in the region of the CCAAT box have been found to act as e-globin 
silencers (Filipe et al., 1999; Tanimoto et al., 2000). Mutation of the 5' DR and both DRs 
in the context of YAC transgenic mice leads to e-globin expression at levels of -1 and 
4.5% relative to yolk sac expression levels, respectively (Tanimoto et al., 2000). This is 
almost four times more induction than was seen when comparing the -1 82 to -467 
deletion mice to wild type mice at 11 dpc (4.5% vs. 1.4%) (Raich et al., 1990; Raich et 
al., 1992). Characterization of MEL cell nuclear extracts identified a novel complex, 
DRED (direct repeat erythroid definitive), that binds to the inverted DRs only during 
definitive erythropoiesis (Tanimoto et al., 2000). Further characterization of the complex 
showed it to contain the nuclear orphan receptors TR2 and TR4 as a heterodimer (Tanabe 
et al., 2002). The autonomous silencing of the human e-globin gene has been mapped to 
four regulatory regions. Deletions or point mutations in these regions lead to adult 
expression in the context of transgenic mice. The regions include, relative to the cap site, 
-3000, between -2000 and -460, -460 to -180, and the proximal promoter (Li et al., 
1998a; Li et al., 1998b; Raich et al., 1995; Wada-Kiyama et al., 1992). However, none of 
these elements is able to restore expression to levels seen in the yolk sac and, in addition, 
no studies have been undertaken where multiple silencing elements have been eliminated. 
This suggests that additional silencing elements are or there are other mechanisms of 
silencing. In addition, factors specific for primitive erythropoiesis may be required to 
achieve high levels of €-globin expression in the adult. 
Unlike the €-globin gene, the y-globin gene is regulated by a combination of 
autonomous silencing and competition. In transgenic mice made from a construct 
containing portions of the LCR, both the y-globin gene and the 0-globin gene show 
correct expression profiles during development (Behringer et al., 1990; Enver et al., 
1990). In contrast, mice containing the LCR and only the y-globin gene show incorrect 
developmental regulation of the y-globin gene, since the y-globin gene is expressed in 
adult mice (Behringer et al., 1990; Enver et al., 1989). These data indicate that the 
presence of the 0-globin gene is needed to silence the y-globin gene during development, 
presumably by competing for LCR-mediated enhancer activity. However, another study 
using a different LCR-y-globin gene construct showed the correct developmental 
silencing of the y-globin gene in the absence of other competing globin genes, 
illuminating an autonomous silencing mechanism (Dillon and Grosveld, 1991). These 
differences may be accounted for by the different constructs used in each study. Despite 
these contradictory studies, it is generally accepted that both autonomous silencing and 
competition each contribute to some degree to y-silencing during development. 
Sequences within the pron~oter play a crucial role in y-globin gene regulation. This point 
is illustrated when looking at non-deletional mutants of hereditary persistence of fetal 
hemoglobin (HPFH). Individuals wi.th HPFH express increased levels of fetal 
hemoglobin as adults due to either genetic deletions or point mutations. Many of the 
described point mutations of HPFH are due to single base pair substitutions in the y- 
globin promoter region (Table 1). Thus, the promoter region of the y-globin gene 
contains important regulatory elements for maintaining y-globin gene suppression. The 
two identical y-globin gene promoters each contain a canonical TATA box, a duplicated 
CAAT box within a 27 bp segment, and a single CACCC box. Located between the 
CAAT box and TATA box is a G-rich sequence possessing a binding activity called stage 
selector protein (SSP) (307, 308). Mutation of the SSP binding site results in down- 
regulation of the y-globin gene only when competing for the P-globin gene during the 
second switch (Ristaldi et al., 2001). There are 2 CpG dinucleotides within the SSP 
binding site, the stage selector element (SSE), at -55 and -50 relative to the transcription 
start site. When these sites are methylated, Spl binds more readily than SSP. These data 
indicate that SSP may bind the SSE as an activator while Spl may mediate repression of 
the y-globin gene when the SSE is methylated, as is seen in adult erythroid cells 
(Humphries et al., 1985). However, mice that contain the human P-globin locus but lack 
functional Spl still express the y-globin gene, indicating that it is not functionally 
important in vivo or that another factor can compensate for its loss (Marin et al., 1997). 
Table 1 : List of non-deletional mutations of hereditary persistence of fetal hemoglobin 
(Stamatoyannopoulos and Grosveld, 2001). 
Type and Ethnic Group 
Normal 
Japanese 
Australian 
BlackJSardinian 
Tunician 
Black 
Georgian 
Black 
Greek 
Cretan 
Black 
Brazilian 
ChineseIItalian 
British 
Georgian 
Mutation 
GY-114 c  to^ 
GY-114 c to G 
Gy-175 T to C 
Gy-200 +C 
Gy-202 C to G 
A y _ 1 1 4 ~   to^ 
A y- 1 14 to - 102 deleted 
* y - l 1 4 ~ t o ~  
Ay-158 C t o T  
Ay-175 T to C 
A y-195 C to G 
Ay-196 C to T 
Ay-198 T to C 
A y-202 C to T 
HbF% 
0.5-1 
11-14 
8.6 
17-30 
18-49 
15-25 
3-6.5 
30-32 
10-20 
2.9-5.1 
36-41 
4.5-7 
14-2 1 
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Mutation of the CACCC and TATA boxes in transgenic mice and transfected cells 
interferes with competition and leads to an increase in 0-globin transcription at the 
expense of the y-globin gene (Sargent et al., 1999; Sargent and Lloyd, 2001). The 
CACCC box is the binding site for the zinc finger Kriippel like proteins. The erythroid 
specific EKLF is crucial for P-globin activation and mice null for EKLF are embryonic 
lethal due to severe anemia (Nuez et al., 1995; Perkins et al., 1995). EKLF is specific for 
0-globin gene expression, despite the fact that both the y- and c-globin genes possess 
CACCC boxes. Therefore, it was postulated that there exists a CACCC-binding factor 
that specifically enhances E- and/or y-globin expression during development. However, 
given the large number of known KLFs, no factor specific y-globin expression has 
emerged (Zhang et al., 2005). However, KLF2 has emerged as an activator of the E- 
globin gene, but not .the y-globin gene, indicating that another KLF or redundancy plays a 
role in regulation of the y-globin by the CACCC box (Basu et al., 2005). Similar to the E -  
globin gene, DRED mediated transcriptional repression at DR elements of the y-globin 
gene has been described (Omori et al., 2005). In addition, a silencer element has been 
mapped using transgenic mice to -378 to -730 relative to the transcription start site 
(Stamatoyannopoulos et al., 1993). Cis elements located within the promoters of both the 
human E- and y-globin genes contribute to the transcriptional regulation of the genes 
during development. 
Mechanisms for y-globin transcriptional repression have also been postulated to 
occur at sites distant from the y-globin gene region. Increased expression of fetal 
hemoglobin in the absence of any known deletional or non-deletional HPFH mutation has 
been described. Mapping studies have linked regions of chromosome 6, 8, and X as 
potential modifiers of y-globin expression (Chang et al., 1995; Gamer et al., 2004; Thein 
and Craig, 1998; Wyszynski et al., 2004). Potential candidate genes in these regions 
include Hbsll,  GGH, DEPDC2, PIK3C2A, GPM6B, TSPYLI, and ZHX2. Thus, 
regions outside of the y-globin gene may contribute to the transcriptional silencing of the 
y-globin gene during development. 
DNA Methylation 
Epigenetic phenomena are biological processes that cause heritable changes in 
gene expression without affecting the sequence of the gene itself. DNA methylation is the 
prototypic epigenetic modification involving the addition of a methyl group to the carbon 
5 position of the cytosine ring in a CpG dinucleotide by a DNA methyltransferase 
(DNMT). Cytosine is the only base known to be methylated in eukaryotic DNA. 
However, methylated cytosine is highly unstable and mutagenic. The number of CpG 
dinucleotides is estimated to be 20% of what would be expected based on the base 
composition of DNA owing to the spontaneous deamination of methylated cytosine to 
thymine (Bird, 1980). Regions of the genome containing the expected frequency of CpG 
dinucleotides have been termed "CpG islands." They are defined as regions that range 
from 200 bases to several kilobases in length, with a G + C content greater than 50%, and 
having a ratio of CpG to GpC greater than 0.6 (Gardiner-Garden and Frommer, 1987). 
These CpG islands are believed to represent regions of the genome that have remained 
unrnethylated and thus spared from the deamination process. 
The DNA methyltransferase enzymes catalyze the addition of a methyl group to 
the CpG dinucleotide. DNA methyltransferase 1 (DNMTl) is considered the maintenance 
methyltransferase as it preferentially methylates hemi-methylated DNA during S-phase 
(Leonhardt et al., 1992). DNMT3a and 3b preferentially methylates unmethylated DNA 
and are considered to be "de novo" methyltransferases (Yokochi and Robertson, 2002). 
The importance of DNA methylation is clearly evident in the embryonic lethal phenotype 
of DNMTl or DNMT3 knock-out mice (Li et al., 1992; Okano et al., 1999). 
Often there exists an inverse correlation between the level of DNA methylation 
and transcriptional activity: hypennethylated regions of DNA are transcriptionally silent 
and hypomethylated regions are active. The exact mechanism of DNA methylation 
induced transcriptional silencing has not been completely discerned, but mechanisms 
have been proposed (Singal and Ginder, 1999). One mechanism involves direct inhibition 
of factor binding. AP-2, cMycIMym, the cyclic AMP-dependent activator CREB, E2F, 
and NF-KB have been shown to have impaired binding upon DNA methylation. On the 
contrary, many transcription factor binding sites lack CpGs and some factors (Spl and 
CTF) can bind regardless of methylation status (Tate and Bird, 1993). 
A second mechanism involves the binding of transcriptional repressors directly to 
methylated DNA. The discovery of a family of proteins, the methyl-CpG binding proteins 
(MCBP), that specifically bind to methylated DNA has led to the theory that these 
proteins act as the mediators of transcriptional repression by DNA methylation (Chen et 
al., 2003; Hutchins et al., 2002; Lin and Nelson, 2003; Magdinier and Wolffe, 2001; 
Sarraf and Stancheva, 2004; Zucker et al., 1983). There are currently six well 
characterized MCBPs, five of which possess a distinct domain, the Methyl-CpG Binding 
Domain (MBD) that is necessary and sufficient for binding of the proteins to methylated 
DNA: MeCP2, MBD1, MBD2, MBD3, and MBD4 (Nan et al., 1993). The sixth protein, 
Kaiso, binds to methylated DNA via its zinc-finger domains and lacks a true MBD 
(Daniel et al., 2002). 
MBD2 binds more avidly to methylated DNA in vitro as CpG density increases, 
however it has been shown to bind to as few as three methylated CpGs in vitro (Fraga et 
al., 2003). MBD2 was identified in the purification of the MeCP-1 complex, the first 
methyl-CpG specific binding activity to be described (Feng and Zhang, 2001). This 
protein complex consists of MBD2 and the Nucleosome Remodeling and Deacetylation 
(NuRD) complex: Mi-2, MTA1, MTA2, MBD3, HDAC1, HDAC2, RbAp46, RbAp48. 
Targeted knock-out of the MBD2 gene in mice generates a mild phenotype consisting of 
a decrease in maternal-nurturing of pups (Hendrich et al., 2001). Loss of MBD2 is also 
associated with dysregulation of the IL-4 gene in Thl and Th2 lymphocytes (Hutchins et 
al., 2002). In addition, lack of MBD2 appears to prevent intestinal tumorigenesis in a 
mouse model (Sansom et al., 2003). However, there are no other genes known to be 
primarily regulated by MBD2 in non-cancerous cells. 
MeCP2 is able to bind to a single symmetrically methylated CpG (Meehan et al., 
1992). MeCP2 contains a transcriptional repression domain (TRD) and has been shown 
to interact with the Sin3a transcriptional repression complex (Nan et al., 1997). However, 
this interaction is unstable, but a stable interaction between MeCP2 and Brahma, a 
component of the SWVSNF nucleosome remodeling complex, has been reported 
(Harikrishnan et al., 2005; Klose and Bird, 2004). In addition, MeCP2 recruits histone 
methyltransfersase activity to the H19 gene (Fuks et al., 2003). MeCP2, unlike MBD2, 
shows sequence specificity as it preferentially binds to CpGs with adjacent AIT tracks 
(Klose et al., 2005). Mice null for MeCP2 have a severe phenotype similar to Rett 
Syndrome, a human neurodevelopmental disorder leading to loss of voluntary movement 
(Guy et al., 2001). Specifically, the Bdnf and D1x5 genes have been shown to be 
regulated by MeCP2 in vivo (Chen et al., 2003; Horike et al., 2005; Martinowich et al., 
2003). 
MBDl has been identified as a critical conlponent of an S-phase specific complex 
that propagates the DNA methylation signal into dimethylation of lysine 9 of histone H3 
during DNA replication (Sarraf and Stancheva, 2004). In addition, mice lacking 
functional MBDl have deficits in hippocampal function (Zhao et al., 2003). MBD3 is a 
core component of the NuRD complex and has been shown to associate with MBD2, 
Ikaros, GATAI, and FOG (Hong et al., 2005; Kim et al., 1999; Rodriguez et al., 2005; 
Zhang et al., 1999). MBD4 functions as a mismatch-specific T/U DNA glycosylase, 
recognizing the product of spontaneous deamination of a methyl-CpG dinucleotide and 
excising it (Hendrich et al., 1999). The Kaiso factor contains a transcriptional repressor 
domain in addition to a zinc finger domain that confers sequence specificity, but lacks an 
MBD (Prokhortchouk et al., 2001). Kaiso has been reported to interact with the N-Cor 
complex to mediate DNA methylation dependent repression of the MTA2 gene (Yoon et 
al., 2003). The zinc fingers of Kaiso can bind methylated DNA or the Kaiso binding site 
(Daniel et al., 2002). No Kaiso knock-out mice have been generated, but the Kaiso gene 
has been shown to be essential for Xenopus developn~ent (Ruzov et al., 2004). 
MCBPs appear to be most crucial to neural development as genetic knock-out of 
MBD2, MeCP2, and MBD1 all display a neural deficit phenotype. Knock-out of these 
proteins is not lethal, unlike the DNMT knock-outs, suggesting each MCBP regulates 
only a sub-set of genes or that MCBPs can compensate for each other. MBD2 has been 
shown to bind to MeCP2 sites after knock-down of MeCP2, however, MeCP2 was unable 
to bind to MBD2 sites after knock-down of MBD2 (Klose et al., 2005). Thus, MeCP2 has 
more sequence specificity for binding methylated CpGs than MBD2. This may account 
for the more severe phenotype of M ~ C P ~  null mice versus MBD2 null mice. 
Interestingly, mice null for MBD3 are embryonic lethal (Hendrich et al., 2001). MBD3 is 
a core component of the NuRD complex. The NuRD complex is a transcriptional 
repression coniplex shown to interact with many proteins including MBD2. Thus, loss of 
a key transcriptional repression complex is more severe than loss of a single MCBP. In 
the absence of a MCBP, complexes such as NuRD are still able to interact with other 
MCBPs. Therefore, the only genes dysregulated will be those that possess sequence 
specific binding sites. On the other hand, loss of a transcriptional repression complex, for 
example NuRD in the absence of MBD3, cannot be compensated for by another MCBP. 
This may account for the phenotypic differences between MCBP knock-out mice and 
MBD3 knock-out mice. 
DNA Methylation and Globin Gene Regulation 
DNA methylation was first hypothesized to play a role in gene regulation over 30 
years ago (Holliday and Pugh, 1975; Riggs, 1975; Scarano, 197 1). The first correlation 
between transcriptional activity and DNA methylation was seen in chicken adult red 
blood cells (McGhee and Ginder, 1979). Subsequently, similar results were seen in other 
species (Atweh et al., 2003; Mavilio et al., 1983; Shen and Maniatis, 1980; van der Ploeg 
and Flavell, 1980). These studies came to the same conclusion that actively transcribed 
genes were in general hypomethylated around the promoter whereas silent genes were 
hyperrnethylated. The globin genes were the first genes shown to be regulated in part by 
DNA methylation and were among the first genes shown to be up-regulated by the 
DNMT inhibitor 5-azacytidine, a cytosine analogue that incorporates into DNA and 
covalently binds to DNMTs leading to their inhibition. 5-azacytidine was first shown to 
increase fetal hemoglobin (HbF, y2@) in anemic baboons (DeSimone et al., 1982). 
Similar induction of silenced embryonic and fetal globin genes by 5-azacytidine has been 
reported in chickens, MEL cells, MEL cells containing human chromosome 11, and mice 
harboring a YAC transgene (Atweh et al., 2003; Ginder et al., 1984; Ley et al., 1984; 
Pace et al., 1994; Zucker et al., 1983). Taken together, these results indicate DNA 
methylation plays a role in globin gene silencing during development. In addition, 
methylation of the avian embryonic p-globin gene inversely correlates with its expression 
during development (Singal et al., 1997). 
Interestingly, co-administration of 5-azacytidine with the short chain fatty acid, 
butyrate, was shown to synergistically increase expression of fetal hemoglobin in 
baboons and err~bryonic p-globin in chickens versus 5-azacytidine treatment alone 
(Constantoulakis et al., 1989; Ginder et al., 1984). A similar effect, though less 
pronounced, was seen in mice harboring a PYAC transgene (Pace et al., 1994). Short 
chain fatty acids (SCFA), among other functions, inhibit histone deacetylases (HDACs) 
(Swank and Stamatoyannopoulos, 1998). The synergistic increase in globin gene 
expression upon treatment with 5-azacytidine and SCFAs is likely due to the co- 
localization of HDACs with methyl binding complexes. A methyl CpG binding complex 
has been shown to bind the p-globin promoter and proximal transcribed region (Singal et 
al., 2002). Mass spectrometry analysis of the biochemically purified complex showed it 
to contain both MBD2 and HDAC2 (Kransdorf and Ginder, 2004). MBD2 was further 
shown to bind the p-globin promoter and proximal transcribed region in vivo by 
chromatin immunoprecipitation assay (ChIP). Finally, this complex differs in 
biochemical make-up from MeCPl and shows a preference for the p-globin proximal 
transcribed region versus the CG11 construct used to purify MeCPl. This is evidence that 
sequence specific binding of MCBPs may in part be determined by the biochemical 
make-up of the complex it interacts with in a cell and tissue specific manner. Taken 
together, these results indicate a complex interaction between DNA methylation, histone 
acetylation, and histone methylation may be at work to regulate globiii gene expression. 
Induction of Silenced Globin Genes 
Short chain fatty acids alone have shown mixed results in the ability to induce 
globin gene expression. Both sodium butyrate and alpha amino butyric acid were unable 
to induce expression of silenced globin genes in anemic chickens or PYAC transgenic 
mice (Ginder et al., 1984; Pace et al., 1994). However both sodium butyrate and 
proprionate were able to induce mouse ~y expression in MEL cells (Little et al., 1995). 
Increased levels of y-globin mRNA have been seen in patients receiving SCFA treatment 
and in children with metabolic disorders leading to increased levels of SCFAs in the 
serum (Collins et al., 1994; Collins et al., 1995; Little et al., 1995; Olivieri et al., 1997; 
Perrine et al., 1993; Sher et al., 1995). Treatment of m A C  transgenic mice and baboons 
with various short chain fatty acid derivates (SCFAD) induced y-globin mRNA 
expression (Pace et al., 2002). It has yet to be determined whether the SCFADs used in 
the study can produce the same synergistic effect on globin expression as seen when 
combining sodium butyrate or alpha amino butyric acid with 5-azacytidine in chickens 
and transgenic mice. SCFA impact other cellular functions in addition to acting as 
inhibitors of histone deacetylation. For example, butyrate has been shown to arrest cell 
growth in G1 phase, induce protein synthesis, and change cell morphology (Borenfreund 
et al., 1980; Kruh, 1982; Rastl and Swetly, 1978). Induction of the y-globin gene has been 
achieved in the absence of DNA methylation and HDAC inhibition. Specifically, y- 
globin mRNA can be induced via manipulation of cell signaling pathways including the 
p38 MAP kinase pathway, the soluble guanylate cyclase-cGMP dependent kinase 
pathway, and the 1-argininelnitric oxide/cGMP pathway (Bhanu et al., 2004; Haynes, Jr. 
et al., 2004; Ikuta et al., 2001; Pace et al., 2003). In addition, induction of y-globin has 
been seen with compounds that do not directly affect epigenetic modifications or cell 
signaling pathways (Bianchi et al., 1999; Bianchi et al., 2001; Lampronti et al., 2003). 
Taken together, the regulation of the globin locus involves cis elements, trans factors, 
and epigenetic modifications. Understanding how all regulatory elements interact is 
crucial to the establishment of proper treatment regimens for patients afflicted with 
hemoglobinopathies. 
Significance 
Hemoglobinopathies are a group of pathologies characterized by a deficency in 
the production of the hemoglobin molecule. Most hemoglobinopathies can be categorized 
into one of two groups. The first group is able to produce structurally normal 
hemoglobin, but erythropoiesis is ineffective (i.e., the thalassemias). The 0-thalassemias 
are a group of disorders characterized by impaired P-chain synthesis leading to 
ineffective erythropoiesis. Homozygous patients often die in their teens or early twenties 
due to the severity of the anemia. The second group produces structurally abnormal 
hemoglobin due to aberrant amino acid substitutions (i.e., sickle cell disease). Sickle cell 
disease (SCD) affects 1 out of every 600 African Americans and is due to a single 
mutation in the amino acid sequence (glutamic acid to valine at position 6 of the P-chain 
subunit). The mutation allows the sickle hemoglobin to polymerize and distort the shape 
of the erythrocyte. As a result, cells lose flexibility and are prone to block the 
microvasculature leading to painful crises. The course of the disease varies from patient 
to patient depending on various parameters. However, the life of a sickle cell patient is 
often shortened and full of pain. Patients with hemoglobinopathies and a genetic mutation 
leading to hereditary persistence of fetal hemoglobin often show less severe to no signs of 
the disorder. In 0-thalassemia, the expression of the y-chain can compensate for loss of 0- 
and &-chain synthesis. The Cooperative Study of Sickle Cell Disease, a large multicenter 
study of the history of SCD, showed an inverse correlation between levels of fetal 
hemoglobin and painful crises and early death (Platt et al., 1991; Platt et al., 1994). Fetal 
hemoglobin was also shown to have a sparing effect on polymerization of 
deoxyhemoglobin S, the cause of membrane deformability in SCD (Poillon et a]., 1993). 
In addition, the 0- and a-embryonic genes, E -  and {-globin, have been shown to inhibit 
the polymerization process in vitro and in vivo (He and Russell, 2002; He and Russell, 
2004). Expression of both these genes was also able to reverse a mouse model of a-  and 
P-thalassemia (Russell and Liebhaber, 1998). The induction of silent globin genes is the 
primary treatment option for patients with hemoglobinopathies. Many clinical trials are 
currently ongoing in an effort to find the best compound(s) to treat these patients (Atweh 
et al., 2003). However, the currently prescribed treatments are either highly toxic or 
ineffective in a subset of patients. Therefore, dissecting the exact mechanism(s) of globin 
gene silencing will lead to safer and more effective treatment options for patients. 
Included in this are compounds that more specifically target the globin gene silencing 
process and possibly gene specific therapy. 
The impact of this study is not solely limited to the realm of hemoglobinopathies. 
Epigenetic modifications have been implicated in many disease processes. Specifically, 
abnormalities in DNA methylation are associated with mental retardation, disorders of 
imprinting, and cancer. Expansion and methylation of a CGG repeat in the FMRl 5' 
untranslated region leads to gene silencing in Fragile X syndrome (Oostra and 
Willemsen, 2002). DNA methylation plays a crucial role in genomic imprinting. 
Dysregulation of the imprinted genes is associated with Angelman syndrome, Prader- 
Willi Syndrome, and Beckwith-Wiedemann Syndrome (Egger et al., 2004). DNA 
methylation also plays a role in the development of many cancers. In fact, epigenetic 
silencing has been recognized as a third pathway satisfying Knudson7s hypothesis that 
two hits are necessary for the silencing of tumor suppressor genes (Jones and Laird, 
1999). For example, the gene encoding MLH1 is often methylated and silenced in 
patients with sporadic colorectal cancers with microsatellite instability phenotype (Kane 
et al., 1997). Thus, discerning the role of epigenetics in globin gene silencing may have a 
direct impact on other disorders where epigentics play a critical role in pathogenesis. 
CHAPTER 2: Generation and Analysis of Globin Gene Regulation in Transgenic 
Knock-out BYACIMBD2-I- Mice 
Introduction 
Methylation of the 5' position of cytosine in the CpG dinucleotide in vertebrates 
is associated with transcriptional repression. A group of proteins, the methyl-CpG 
binding proteins (MCBP), specifically recognizes and binds to DNA sequences 
containing methylated cytosines. Most of these proteins belong to a subgroup based on 
the common features of a characteristic domain, the Methyl-CpG Binding Domain 
(MBD), which is necessary and sufficient for binding of the proteins to methylated-DNA 
(Nan et al., 1993). The MBD protein family consists of MeCP2, MBD1, MBD2, MBD3, 
and MBD4. MBD2 and MeCP2 have been found to bind methylated-DNA as large multi- 
protein complexes (Feng and Zhang, 2001; Jones et al., 1998; Nan et al., 1998). MBD4 
differs from the other MBD proteins in that its primary function is as a DNA repair 
enzyme. DNA methylation mediated transcriptional repression is thought to be due to the 
recruitment of MCBPs and repressive protein complexes to methylated DNA. These 
complexes are thought to mediate transcriptional repression by recruiting histone 
deacetylases and transcriptional repressor proteins to methylated-DNA (Chen et al., 2003; 
Hutchins et al., 2002; Lin and Nelson, 2003; Magdinier and Wolffe, 2001; Sarraf and 
Stancheva, 2004). MBD2 is part of the methyl-CpG binding protein complex 1 (MeCP1) 
which contains Mi-2, MTA1, MTA2, MBD3, HDAC1, HDAC2, RbAp46, and RbAp48 
(Feng and Zhang, 2001). Early studies suggested an interaction between MeCP2 and the 
SIN3A transcriptional repression complex. However, recent evidence indicates this 
interaction may not be stable (Klose and Bird, 2004). Brahma, a component of the 
SWVSNF nucleosonie remodeling complex, does form a stable complex with MeCP2 
(Harikrishnan et al., 2005). The Kaiso factor represents another type of methyl CpG 
binding protein that contains a transcriptional repressor domain as well as a zinc finger 
domain that confers sequence specificity, but lacks an MBD (Prokhortchouk et al., 2001). 
The zinc fingers of Kaiso can bind methylated CGCGs or the Kaiso Binding Site 
TCCTGCNA (Daniel et al., 2002). 
Targeted deletions of methyl CpG binding proteins have yielded insight into the 
functions of these proteins in vivo. Mice null for MBD1 have deficits in adult 
neurogenesis and hippocampal function (Zhao et al., 2003). Mice lacking functional 
MeCP2 display a phenotype similar to Rett Syndrome, a human neurodevelopmental 
disorder leading to loss of voluntary movements (Guy et al., 2001). Loss of MBD2 has a 
milder phenotype with the chief manifestation being decreased maternal nurturing of 
pups (Hendrich et al., 2001). Loss of MBD2 specifically interferes with the regulation of 
the IL-4 gene in mouse Thl and Th2 lymphocytes indicating that MBD2 can contribute 
to the regulation of genes in a tissue specific manner (Hutchins et al., 2002). However, no 
other genes have been reported to be primarily regulated by MBD2 in non-cancerous 
cells. Unlike the embryonic lethal phenotype of DNA methyltransferase (DNMT) knock- 
out mice, loss of MBDs is not catastrophic, indicating MBDs may compensate for each or 
that only a small number of genes required for normal cell function are regulated by any 
specific MBD (Li et al., 1992; Okano et al., 1999). Interestingly, Kaiso, a methyl-CpG 
binding protein not in the family of MBD containing genes, has been shown to be 
essential for Xenopus development (Ruzov et al., 2004). 
The genes of the human P-globin locus are expressed sequentially during 
development in the order they appear on chromosome 11: 5' E - ,  Gy-, *T-, and P-3'. The 
individual genes have been shown to be regulated by a complex interplay between cis 
elements, trans factors, conlpetition for an upstream enhancer, and epigenetics 
(Stamatoyannopoulos and Grosveld, 2001). Despite a tremendous amount of progress in 
this field, the exact mechanism(s) of globin gene silencing is still not understood. The 
initial observation in vertebrates that DNA methylation is inversely related to gene 
expression was noted in the globin locus (McGhee and Ginder, 1979). Furthermore, the 
globin genes were the first group of genes for which the DNA methyltransferase 
inhibitor, 5-azacytidine, was shown to activate silenced embryonic and fetal genes in vivo 
in both animal models and in a therapeutic setting (Charache et al., 1983; DeSimone et 
al., 1982; Ginder et al., 1984; Ley et al., 1982). Previously, we have shown a role for 
DNA methylation and MBD2 in the developmental regulation of the chicken embryonic 
p-globin gene (Bums et al., 1988; Ginder et al., 1984; Singal et al., 1997; Singal et al., 
2002). The p-globin gene becomes highly methylated at the same time the gene becomes 
silent. Furthermore, the p-globin gene is enriched for MBD2 in adult erythrocytes when 
the gene is silent, but not when it is actively transcribed. Finally, a protein complex 
containing MBD2 purified from primary chicken erythrocytes binds to a methylated p- 
globin gene 5' sequence and differs in biochemical make-up from MeCPl (Kransdorf and 
Ginder, 2004). These findings are evidence that MCBPs may form unique tissue 
restricted complexes that are targeted to specific sets of genes. Taken together, this 
evidence suggests MBD2 may be involved in the process of globin gene silencing by 
DNA methylation. 
To determine .the role of MBD2 in mammalian globin gene silencing, mice 
containing the entire human globin locus as a yeast artificial chromosome (PYAC ) were 
bred with mice containing a targeted deletion of MBD2. Adult PYACIMBD2-I- mice 
inappropriately express the y-globin gene at a level commensurate to mice treated with 5- 
azacytidine, while adult PYAC mice express the y-globin gene at much lower level. This 
is, to our knowledge, the first evidence of a specific MCBP regulating y-globin 
expression. In addition, loss of MBD2 delays the silencing of the y-globin gene during 
embryonic development. Loss of MBD2 slightly decreases DNA methylation levels 
around the y-globin pron~oter, and inhibiting DNA methylation does not greatly enhance 
the expression of the y-globin gene, indicating the induction seen in knockout mice is not 
largely dependent on DNA methylation or that the additional effect of 5-azacytidine is 
mediated by a different MCBP. 
Methods 
Generation of PYACIMBD2-I- Mice 
MBD2-I- mice (a generous gift from Dr. Adrian Bird) were mated with PYAC 
mice (a generous gift from Dr. Karin Gaensler). The subsequent flACIMBD2+I- mice 
were bred with MBD2-I- mice to generate PYACIMBD2-I- mice. To maintain the line, 
PYACIMBD2-I- were bred with MBD2-I- mice. All progeny were screened for the 
presence of the transgene and absence of MBD2 using PCR of DNA from tail snips. 
Primers used to screen mice are located in Table 2. Two lines of PYAC mice were used 
to generate transgenic knock-out mice, the A20.1 and A85.68 lines. Both contain a single 
copy of the f l A C  transgene in the C57 B116 background (A20.1) or the FVBIN 
background (A85.68). The MBD2-I- mice are in the BALBIC background. Through 
multiple rounds of breeding to establish and maintain lines, the final transgenic knock-out 
mice were in a heterogeneous genetic background. 
Generation of PYACIMeCP2-I- Mice 
Female MeCP2+/- mice (Jackson Laboratories) were bred with A20.1 f l A C  
transgenic mice. The MeCP2 gene is located on the X-chromosome, therefore only one 
round of breeding was necessary to generate flACIMeCP2-Iy mice. All mice were 
screened for the presence of the transgene and absence of MeCP2 using PCR from tail 
snip DNA (Table 2). 
Red Cell Lndices 
Peripheral blood was extracted from the inferior vena cava of three non-anemic 
mice of each genotype. The blood was collected in a citrate coated lavender top tube. The 
blood was analyzed on a Coulter Hematology Analyzer (Beckman Coulter). 
Reticulocytes were counted manually after staining with methylene blue for 15 minutes at 
37" C. 1000 cells were counted per analysis. 
Timed Matings 
For MBD2 wild type embryos, PYAC males were bred with non-transgenic 
females. For MBD2-I- embryos, mACIMBD2-I- males were bred with non-transgenic 
MBD2-I- females. The presence of a vaginal plug was designated day 0.5. Fetal livers 
were dissected from day 14.5 and 16.5 embryos. 
Treatments 
Mice were treated for two days with intraperitoneal injection of l-acetyl-2- 
phenylhydrazine (1 0 mg/mL, Sigma) at a dose of 0.4 mgIl0g. On the third day, mice 
were treated with 5-azacytidine (0.5 mg/mL, Sigma) at a dose of 2 mglkg for five days 
via intraperitoneal injection. 
RNA Isolation 
RNA was extracted from fetal livers or peripheral blood using Trizol 
(Invitrogen). Fetal livers were homogenized in 200 pL of Trizol in a 1.5 niL tube. The 
volume was then increased to 1 mL with Trizol. Peripheral blood was added directly to I 
mL of Trizol. 200 FL of CHC13 was added to the tube and shaken vigorously for 20 
seconds and allowed to sit at room temperature for 3 minutes. The tube was spun at 
Table 2: List of primers used to screen transgenic and knock-out PYAC0020mice. 
Primer 
Beta 488 NC 
Beta 161 BC 
MBD2-17390-F 
MBD2-17507-R 
bGeo-3084-F 
bGeo-3286-R 
MeCP2 Common 
MeCP2 W O  
MeCP2 W T  
Sequence 
GAGGGGAAAAGGTCTTCTACTTGG 
CCCTACGCTGACCTCATAAATGC 
CCTCAGCTGGCAAGATACCT 
GGGGGTCATTCCGGAGTCT 
GGTCAGGTCATGGATGAGCAGA 
CGCGGATCATCGGTCAGACGATT 
GGTAAAGACCCATGTGACCC 
TCCACCTAGCCTGCCTGTAC 
GGCTTGCCACATGACAA 
12000 x G for 15 minutes at 4' C. The upper aqueous phase was collected and 
precipitated with 83% volume of isopropanol at room temperature for 10 minutes 
followed by centrifugation at 12000xg for 10 minutes at 4OC. The resulting RNA pellet 
was washed with 70% ethanol/30% DEPC-treated water and air dried. The pellet was 
resuspended in DEPC-water containing 1 pL of SuperRNasIN (Ambion) per 40 pL of 
DEPC-water. Fetal liver RNA was further purified by LiCl precipitation. The RNA 
concentration was determined using a UV spectrophotometer. 
RNase Protection Assay 
Single stranded, radiolabeled cRNA probes were synthesized using SP6 
polymerase and ( x _ ~ ~ P  UT  (MP Biomedicals) with various templates. The mouse a-  
globin probe was derived from a 309 bp fragment at the 3' end of the gene cloned into 
pSP6 vector (Curtin et al., 1989). Probes for y-globin analysis were from a 1.7 kb 
fragment of the Ay-globin gene protecting two bands (205, 144bp) when cut with EcoRI 
or one band when cut with NcoI (1 88bp). The fragment was cloned into the pGEM-3zf(-) 
plasmid (Promega). To discriminate between "y- and "yglobin mRNA, a probe identical 
to one used previously was generated by PCR (Morley et al., 1991). The PCR product 
was cloned into the pGEM-EZ plasmid (Promega). The forward primer contained a 
HirzdIII site to make a linear template protecting a 21 5 bp fragment for Ay-globin mRNA 
and a 135 bp fragment for Gy-globin gene. For the detection of y-globin, 500 ng RNA was 
analyzed per RPA. For mouse a-globin analysis, 10 ng of RNA was used per analysis. 
RNA was hybridized overnight at 42OC with 1 x 1 0 ~  cpm of probe in 30 pL of 
hybridization buffer containing 80% formamide. After hybridization, the y-globin and a- 
globin samples were combined for RNase digestion so both samples could be run on the 
same gel. The samples were digested with RNase digestion buffer (300mM NaC1, 10mM 
Tris-C1, pH 7.4, 5mM EDTA, pH 7.5) containing RNase A (Roche, 20 pg per sample) 
and RNase T1 (150 U per sample) at 37°C for 30 minutes. The enzymes were inactivated 
by treating with Proteinase K (60 pg per sample) and SDS (10 pL of 20% stock) at 37OC 
for 30 minutes. The RNA was extracted with phenol and chloroform and ethanol 
precipitated. The samples analyzed on a 6% denaturing polyacrylmide gel containing 7 M 
urea. Band intensity was determined using a Phosphor-Imager (Molecular Dynamics). 
RNA level was determined relative to the amount per copy of mouse cx-globin. 
Bisulfite Conversion 
Mice were treated with 1 -acetyl-2-phenylhydrazine for two days and harvested on 
the fifth or seventh day. Genomic DNA was isolated from spleens using .the Zymo 
Research genomic isolation kit (Zynio Research). The DNA was bisulfite converted using 
the Zynio Research EZ methylation kit. Genomic DNA (- 1 pg) was diluted to 45 pL in 
water and heated at 95" C for 5 minutes. The DNA was further denatured by adding 5 pL 
M-dilution buffer and incubated at 37" C for 15 minutes followed by the addition of 100 
pL of bisulfite conversion solution. The samples were incubated at 50" C overnight. The 
bisulfite converted DNA was purified on a spin-column and eluted in water. Bisulfite 
converted DNA was amplified using nested PCR with primers for either Gy- or *yglobin 
promoter region. Primers were designed so that the last nucleotide in the primer was a 
thyrnidine in the bisulfite converted and cytosine in normal genomic DNA to prevent the 
amplification of non-converted DNA. PCR products were cloned, screened, and 
sequenced. Primers used for bisulfite specific PCR are listed in Table 3. 
Chromatin Immunoprecipitation 
Mice were treated for two days with 1-acetyl-2-phenylhydrazine. On the fifth 
day, spleens were harvested and gently brushed into single cell suspension in ice cold 
W M I  containing 2% FBS, 5 n1M Butyrate, PMSF, aprotinin, leupeptin, and pepstatin. 
Butyrate and protease inhibitors were included in all steps until TE washes. Cells were 
then passed through a 70 pM nylon filter to remove debris. Cells were spun and washed 
with ice cold PBS containing 2% FBS (PBSIFBS). Cells were then resuspended in room 
temperature PBSEBS. Formaldehyde was added drop-wise to a final concentration of 
0.4% and cells crosslinked for 10 minutes at room temperature. The reaction was 
terminated by adding glycine to 0.125M and incubating at room temperature for 5 
minutes. Cells were washed twice with PBSEBS. Cells were resuspended in SDSILysis 
buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1) at a concentration of 25-30 mg 
spleen1200 pL and incubated on ice for 10 minutes. Chromatin (-700 pL with 200 pL 
glass beads) was sonicated by six 20 second pulses at 27.5% on a sonicator fitted with a 4 
mm tip to achieve 200-1 000bp (mean 600bp) DNA. Cellular debris was removed by 
centrifugation at 12000 rpm for 10 minutes at 4OC. The sonicated chromatin was diluted 
ten-fold in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 
mM Tris-HC1, pH 8.1, 167 mM NaC1). Diluted chromatin was pre-cleared with 80 pL 
Table 3: Primers used for bisulfite specific PCR of the y-globin promoter region. 
Primer 
5-A-START- 1 
5-G-START-2 
G-START-2 
A-START-2 
3-END-2 
3-END-1 
Sequence 
GGAGTTATAGATAAGAAGGTC 
GGAGTTATAGATAAGAAGGTG 
GGTATTTTTTATGGTGGGAGAAGA 
GGTATTTTTTATGATGGGAGAAGG 
CCAAAACTATCAAAAAACCTCTAA 
CCTTCTTACCATATACCTTAACTTTTA 
protein A agarose/salmon sperm DNA slurry (Upstate Biotechnology) per 2 mL diluted 
chromatin by rotating at 4°C for 30 minutes. The diluted chromatin was spun at 2000 rpm 
at 4°C for 2 minutes and aliquoted into 2 mL (25 mg spleen) samples for 
immunoprecipiation with anti-acetyl H3 (Upstate Biotechnology), anti-acetyl H4 
(Upstate Biotechnology), anti-Pol I1 (Santa Cruz), rabbit pre-immune serum (Santa Cruz 
Biotechnology), and anti-Trimethyl H3 K4 (Abcam and Upstate), and normal rabbit IgG 
(Upstate Biotechnology) and incubated overnight with rotation at 4°C. A 500 pL aliquot 
was stored at -20°C for use as the input sample. Samples were mixed with 60 pL protein 
A agarose/salmon sperm and rotated for an additional 2 hours at 4" C. Samples were spun 
at 2000 rpm for 2 minutes at 4°C. The supernatant was removed and the beads were 
washed with 1 mL low salt wash (0.1% SDS, 1% Triton X-100,2 mM EDTA, 20 mM 
Tris-HC1, pH 8.1, 150 mM NaC1) by rotating at 4°C for 5 minutes. The beads were spun 
down at 2000 rpm for 2 minutes and washed again with 1 mL high salt wash (0.1% SDS, 
1% Triton X-100,2 mM EDTA, 20 mM Tris-HC1, pH 8.1, 500 mM NaCl). The washing 
process was repeated three more times, once with a LiCl buffer (0.25 M LiC1, 1% 
IGEPAL-CA630, 1 % deoxycholic acid, 1 mM EDTA, 1 OmM Tris-HC1, pH 8.1) and 
twice with TE (10 mM Tris-HC1, 1 mM EDTA, pH 8.0). After the final wash, the 
immune complexes were eluted by adding 250 pL elution buffer (0.1 M NaHC03, 1 % 
SDS), vortexing briefly, and rotating at room temperature for 20 minutes. The beads were 
then spun down at 2000 rpm for 2 minutes at room temperature and the supernatant 
collected. The beads were then eluted a second time with 250 pL of elution buffer. The 
formaldehyde crosslinks were reversed by adding 50 pL 3 M NaCl and 1 pL RNase A 
(20 mg/mL) and heating at 65" C overnight. Protein was digested by adding 20 pL Tris 
pH 6.5, 10 pL 0.5 M EDTA, and 1 pL Proteinase K (20 mg/mL) and incubating at 45" C 
for 2 hours. The samples were then extracted once with phenol and CHC13 and once with 
chloroform followed by ethanol precipitation. DNA pellets were dissolved in water and 
quantitated using the PicoGreen assay (Molecular Probes, Carlsbad, California). The 
amount of globin gene present in the immunoprecipitated samples was determined by real 
time PCR using ~ a ~ ~ a n ~ "  probes (Perkin-Elmer Applied Biosystems) on an ABI 7500 
or 7900 HT. The levels of enrichment were normalized to the non-specific mouse 
amylase gene to account for variations during immunoprecipitations. Primer and probe 
sequences used for real-time PCR analysis are located in Table 4. ChIP analysis 
performed on fetal livers was identical to the above procedure with the following 
exceptions. Frozen fetal livers were thawed and gently pipetted into a suspension. Half a 
fetal liver was used per immunoprecipitation. 
RT-Real-Time PCR 
RNA (3.7 pg) was first treated with DNase I using the Turbo DNA-Free 
(Ambion). DNase-treated RNA (1 pg) was reverse transcribed using Script (Bio-Rad) 
cycling at 25" C for 5 minutes, 42" C for 30 minutes, and 85" C for 5 minutes. cDNA was 
analyzed using y-globin primers (25 ng) and mouse a-globin primers (5 ng) and SYBR 
green chemistry on an ABI 7500 or 7900HT Sequence Detection System. Levels of y- 
globin expression were normalized to endogenous mouse a-globin expression. Primer 
sequence used for real-time PCR analysis are found in Table 5. Additional analysis was 
Primer Sequence 
GammaIn2-F GGAGATGTTTCAGCACTGTTGCCT 
GammaIn2-R 1 AGCCCAGTTAGTCCTCTGCAGTTT 
Amylase-F AGTTCGTTCTGCTGCTTTCCCTCA 
Amylase-Probe tetTTCTGCTGGGCTCAATATGACCCACAtamra 
Amylase-R I TTCCTTGGCAATATCAACCCAGCG 
hBetaExn#2-F 1 TACCCTTGGACCCAGAGGTTCTTT 
hBetaExn#2-R TAAAGGCACCGAGCACTTTCTTGC 
I 
Table 4: List of primers used for real-time PCR analysis of ChIP assay DNA in Chapter 
2. 
MouseBetaHl -F 
MouseBetaH 1 Probe 
Mouse Beta HI -R 
Mouse Ey-F 
Mouse Ey-Probe 
Human E-globin-F 
Human E-globin-Probe 
Primer 
Human €-globin-R 
Human y-globin-F 
Sequence 
Human y-globin Probe 
Human y-globin-~ 
Mouse GlycophorinA-F 
Mouse GlycophorinA-P 
Mouse GlycophorinA-R 
Mouse zeta-F 
Mouse zeta-Probe 
AGGCAGCTATCACAAGCATCTG 
6famGAAACTCTGGGAAGGCTCCTGATTGTTTACCtamra 
AACTTGTCAAAGAATCTCTGAGTCCAT 
CAAGCTACATGTGGATCCTGAGAA 
6famTCAAACTCTTGGGTAATGTGCTGGTGATTGtamra 
GCCTTTGCTAAGCTGAGTGAG 
6famTCAAGCTCCTGGGTAACGTGATGGTGAtamra 
TTGCCAAAGTGAGTAGCCAGAA 
GTGGAAGATGCTGGAGGAGAAA 
6famAGGCTCCTGGTTGTCTACCCATGGACCtamra 
TGCCATGTGCCTTGACTTTG 
GCCGAATGACAAAGAAAAGTTCA 
6famTTGACATCCAATCTCCTGAGGGTGGTGAtamra 
TCAATAGAACTCAAAGGCACACTGT 
GCGAGCTGCATGCCTACAT 
6famTGGATCCGGTCAACTTCAAGCTCCTGTtamra 
I Mouse zeta-R I 
Malpha-2 F 1 AATATGGAGCTGAAGCCCTGG 
I I I 
Table 5: Primers used for real-time PCR expression analysis in Chapter 2. 
I Ma1pha-2 ACATCAAAGTGAGGGAAGTAGGTCT I 
performed using ~ a ~ m a n ~ ~  probes for detections of glycophorin A, human c-, cy-, phl-, 
and {-globin transcripts (Table 5). 
Results 
Two lines of mice containing the entire human 6-globin locus as a yeast artificial 
chromosome (PYAC) were used in these studies, A20.1 and A85.68 (Figure 4) (Porcu et 
al., 1997). PYAClMBD2-I- mice were generated by breeding PYAC mice with MBD2-I- 
mice and breeding the subsequent transgenic hemizygotes with MBD2-1- mice. 
PYACMBD2-I- mice were treated with 1 -acetyl-2-phenylhydrazine to induce hemolytic 
anemia for the purpose of increasing the number of reticulocytes for RNA analysis. 
Peripheral blood was collected on the third day after treatment. For 5-azacytidine 
treatment, PYACIMBD2+1+ mice were treated for 2 days with 1 -acetyl-2- 
phenylhydrazine followed by 5 days of intraperitoneal5-azacytidine treatment. Peripheral 
blood was collected the day after the final treatment. Globin gene expression was 
analyzed using the RNase protection assay. As seen in Figure 5, y-globin mRNA was 
barely detectable by this assay in adult PYAC/MBD2+/+ mice and PYAC/MBD2+/- 
mice. However, PYAClMBD2-I- and PYAC/MBD2+/+ mice treated with 5-azacytidine 
express the silenced y-globin gene at similar increased levels. Both A20.1 PYACMBD2- 
I- and PYAC mice treated with 5-azacytidine express the y-globin gene at -2% of mouse 
alpha globin (Figure 6). A slightly higher level of expression is seen in MBD2 null mice 
derived from A85.68 PYAC transgenic mice. In addition, this effect is seen in MBD2-I- 
LCR 3' HSS 
Figure 4: Constructs used to generate PYAC transgenic mice. The top line is a 
representation of the human P-globin locus. The A20.1 constructs contains -150kb of 
sequence while .the A85.68 contains >200kb of sequence. The vertical gray bars indicate 
the position of the genes in the locus; Black arrows indicate DNase I hypersensitive sites. 
Horizontal gray bars indicate YAC arms. LCR = locus control region. HSS = DNase I 
hypersensitive site. 
Figure 5: RPA analysis of y-globin expression in wild type and MBD2 null PYAC 
transgenic mice. Both lines of f lAC transgenic mice express nominal levels of 7-globin 
mFWA in the MBD2+/+ and MBD2+/- background. Treatment with 5-azacytidine or loss 
of functional MBD2 leads to a pronounced increased in y-globin expression in both lines. 
Treatment of a 20.1 PYACIMBD2-I- mouse with 5-azacytidine leads to slight additive 
boost in yglobin expression. The endogenous mouse a-globin gene was used as a loading 
control and was hybridized using 50-fold less RNA. The samples were hybridized 
separately and combined for RNase digestion. 
MBD2-I- MBDZ+I+ MBD2-1- 
and +I- 
Figure 6: Quantitative analysis of y-globin expression in wild type and MBD2 null PYAC 
transgenic mice. Bands from RPA were quantitated using a phosphor-imager. The level of 
expression of the y-globin gene was calculated relative to the per copy expression of the 
mouse a-globin gene. Shown above are the results from the A20.1 line of PYAC transgenic 
mice and the A85.68 line of PYAC transgenic mice. Either treatment with 5-azacytidine or 
loss of MBD2 results in expression of the y-globin gene to -2% of mouse a-globin 
expression. The results shown are the average of three RPAs from at least two different 
mice. For the A85.68 mice, the MBD2+/+ and +/- is the average value from one mouse of 
each genotype. 
mice not made anemic with 1-acetyl-2-phenylhydrazine (Figure 7). No endogenous 
mouse embryonic globin transcripts were detectable by RNase protection assay (Figure 
8). Very low levels of endogenous mouse globin genes are detected by real-time PCR, 
however, they show large error bars indicating inconsistent low level expression that does 
not differ between genotype or treatment (Figure 8). The effect on human €-globin 
expression is discussed in Chapter 3. However,,we have observed that a human epsilon 
transgene containing a full LCR and 4 kb of downstream flanking sequence but no y- or 
0-globin gene is activated in the MBD2-I- background. Thus, MBD2 is necessary for 
maintaining near complete y-globin silencing in adult mice and loss of MBD2 resuIts in 
markedly increased y-globin expression but not mouse or human embryonic 0-type 
globin genes. This is likely due to the ability of the fetal gene but not the embryonic' 
genes to partially compete with adult @-globin gene for the LCR. In addition, the level of 
induction after treatment with 5-azacytidine is additive, not synergistic, indicating MBD2 
and 5-azacytidine likely work through the same mechanism via DNA methylation. 
Alternatively, the additive increase in y-globin mRNA may be due to the cytoxic effect of 
the compound or compensation by a different methyl CpG binding protein. The 
percentage of 'y- vs. Ay-globin was determined using an RNase protection assay probe 
that discriminates between the two genes (Morley et al., 1991). The % Ay-globin mRNA 
was 60% for PYAClMBD2-I- mice and 70% for PYAClMBD2-tl-t mice treated with 5- 
azacytidine (Figure 9). These values are very similar to the level seen in adult human F- 
cells and opposite to the "y- to Gy-globin ratio in K562, cells suggesting that the y-globin 
mFWA is from cells with a definitive program rather than due to a reactivation of 
Figure 7: Real-time PCR was performed on peripheral blood taken from non-anemic 
MBD2+/+ and MBD2-1- A20.1 PYAC transgenic mice. The relative level of y-globin 
expression was determined relative to glycophorin A. The results indicate that the y- 
globin gene is expressed even when MBD2-1- mice are not treated with 1 -acetyl-2- 
phenyl-hydrazine. 
Bhl  /GIyA 
ey/GlyA 
Figure 8: Treatment with 5-azacytidine treatment or loss of MBD2 does not induce 
expression of any endogenous embryonic globin gene. The top panel shows an RPA of 
cy- and r-globin expression in MBD2+/+ and MBD2-1- peripheral blood. W A  analysis 
was unable to detect expression of either globin gene. The bottom panel shows real-time 
PCR analysis of endogenous globin gene expression in MBD2+/+ mice, MBD2+/+ mice 
treated with 5-azacytidine, MBD2-1- mice, and MBD2-1- mice treated with 5-azacytidine. 
Low levels of all transcripts are detectable, but no significant increases are observed after 
5-azacytidine treatment or after loss of MBD2. In addition, the level of expression is 
>1000-fold less than that seen in the 10.5 dpc yolk sac. 
Figure 9: Ratio of Ay-globin to total y-globin expression in P A C  transgenic mice treated 
with 5-azacytidine and PYAC mice null for MBD2. The RPA probe used in the top panel 
discriminates between the and Gy-globin genes. The ratio of the two genes was 
determined by phosphor-image analysis and indicates that the level of expression of the 
A y-globin gene is slightly higher in both 5-azacytidine treated mice and MBD2 null mice. 
K562 cells show a preference for 'yglobin gene expression. 
primitive erythropoiesis. Red cell indices were compared between non-anemic wild-type 
and knock-out mice. The results show no significant difference except for slight 
microcytosis in MBD2 null mice (Table 6). 
Adult erythroid cells from mice lacking MBD2 inappropriately express the y- 
globin gene. We next wanted to determine the impact of MBD2 on globin gene 
expression during development. Timed matings were performed and embryos harvested 
on 14.5 and 16.5 days post coitus (dpc). At 14.5 dpc, embryos lacking MBD2 expressed 
2-fold more y-globin than wild type embryos (Figure 10). This difference increased to 
3 -5-fold in 16.5dpc fetal livers (Figure 10). The effect seen in adult knock-out mice 
appears to be at least partly due to an inability to fully silence the y-globin gene during 
the switch to definitive erythropoiesis. Therefore, the effect is specific for the y-globin 
and not the embryonic globin genes in the context of PYAC transgenic mice. 
Lack of MBD2 results in expression of the y-globin gene in adult PYAC 
transgenic mice. MCBPs bind to methylated DNA and recruit factors that lead to 
transcriptional repression. In addition, MBD2 has been shown to colocalize with DNA 
methyl transferase 1 (DNMT1) (Tatematsu et al., 2000). We therefore postulated that if 
MBD2 binds at or near the y-globin gene promoter the effect seen in adult PYACIMBD2- 
I- mice may be accompanied by a loss of DNA methylation around the y-globin 
promoter. Bisulfite sequencing was performed to detem~ine the methylation status in 
,8YACIMBD2+I+ mice, PYACIMBD2-tI-t mice treated with 5-azacytidine, and 
PYACIMBD2-I- mice. A 70bp region containing four CpGs was analyzed around the y- 
0 
14.5 dpc 46.5 dpc 
Figure 10: Expression of the y-globin gene during development in MBD2+/+ and MBD2- 
I- PYAC transgenic mice. The level of expression of the y-globin gene was determined 
during development in MBD2+/+ and MBD2-1- PYAC transgenic mice by RPA. During 
development, loss of MBD2 results in increased expression of the y-globin gene in 14.5 
and 16.5 dpc fetal liver erythroid cells. 
MBD2+/+ 
MBD2-1- 
P-Value 
Table 6: Red blood cell indices were determined on three mice of each genotype. P- 
values were calculated by student t-test. 
RBC 
7.6h1.1 
6.72r1.6 
0.42 
Hb 
13.2*1.2 
11.7h2.7 
0.41 
Hct 
37.22r5.1 
30.32r8.1 
0.28 
MCV 
49.32r1.5 
44.6*0.3 
0.01 
MCH 
17.52r0.9 
I 
17.2h0.4 
0.64 
HCHC 
35.8h1.8 
38.6h1.2 
0.08 
Retic 
6.22r0.9 
5.9h1.5 
0.73 
globin promoter. As shown in Figure 1 1, wild type adult erythroblasts show a high level 
of methylation (75-100%) at each CpG tested in the y-globin gene. Furthermore, no 
individual clone (represented as a row in Figure 8) was either completely or 175% 
unmethylated indicating all cells are highly methylated around the y-globin promoter. 
Treatment with 5-azacytidine led to a decrease in methylation at all sites (40-60% 
methylated) with 4 clones having no methylation at any site tested. This result is similar 
to results seen in MEL cells containing human chromosome 11 and primary erythroid 
cells of patients treated with 5-azacytidine (Humphries et al., 1985; Ley et al., 1984). 
Most MBD2-I- clones show an intermediate level of DNA methylation at each site (60- 
90% methylated). In addition 1 clone is fully demethylated while another is 75% 
demethylated. DNA methylation levels are only modestly decreased in the absence of 
MBD2 compared animals treated with 5-azacytidine. This may be the result of increased 
transcription of the gene preventing DNA methylation by DNMT rather than MBD2 
recruiting DNMT activity to the y-globin promoter. Nevertheless, y-globin mRNA levels 
can be increased in the absence of significant loss of DNA methylation around the 
promoter and proximal transcribed regions. This suggests 5-azacytidine and MBD2 exert 
their effect directly at the y-globin promoter region. 
To determine whether loss of MBD2 alters post-translational histone modification 
around the y-globin gene, chromatin immunoprecipitation (ChP)  assays were performed. 
Both PYACIMBD2+I+ and PYACIMBD2-I- mice were treated with l-acetyl-2- 
phenylhydrazine to promote conversion of the spleen to a primarily erythroid organ 
Wild Type pYAC 
Wild Type PYAC + aza 
Figure 1 1 : Bisulfite analysis of MBD2+/+ and MBD2-1- D A C  transgenic mice. 
Genomic DNA from the spleens of anemic mice was treated with bisulfite. The y- 
globin gene promoter region was amplified by PCR, cloned, and sequenced. The 
numbers above each figure indicate the position of CpG relative to the transcription 
start site. The horizontal row indicates one sequenced clone with white bars indicating 
an umethylated CpG, a black bar indicating a methylated CpG, and a gray bar 
indicated an undetermined CpG. 
(Spivak et al., 1973). Splenic erythroblasts were used for chromatin immunoprecipitatioi~ 
with antibodies directed against acetylated histone H3 (AcH3), acetylated histone H4 
(AcH4) and trimethylated lysine 4 of histone H3 (TriMeK4), all of which are associated 
with active transcription. Given that the level of y-globin mRNA is -2% of mouse a- 
globin mRNA in 0YACIMBD2-I- mice, we postulated that any effect on histone 
modifications might be too small to determine. For this reason, the amount of enrichment 
was normalized to the level seen in the inactive endogenous amylase gene control. 
Immunoprecipitations were performed on two mice of each genotype. Shown in Figure 
12 is the average gamma globin to amylase gene ratio for wild type and knockout mice. 
The y-globin promoter region shows enrichment for AcH4, Pol 11, and TriMeK4 in 
knock-out mice and no enrichment for these modifications in wild-type mice. 
Additionally there is little change in the level of AcH3 in either genotype. Additionally, 
the 5' region of the y-globin gene coding region is enriched -4-fold over baseline for 
TriMeK4 in MBD2-1- mice while MBD2+/+ mice show baseline levels. Similar levels of 
enrichment are seen when normalizing the gamma globin value to the active human 0- 
globin gene. The level of enrichment at the highly expressed 0-globin gene is > 20-fold 
higher than enrichment levels at the y-globin gene in MBD2 null mice (Figure 13). A 
similar relationship between level of mRNA expression and active histone modification 
enrichment is seen in mice containing a mutant human PYAC transgene that expresses 
the human 0-globin gene at 3% of the normal transgene (Fang et al., 2005). The 
enrichment of TriMeK4 in MBD2-I- mice may be due to the recruitment of histone 
LCR 3' HSS 
Figure 12: Analysis of post-translational histone modifications at the y-globin gene 
promoter and coding regions in wild type and MBD2 null PYAC transgenic mice. ChIP 
assays were performed on splenocytes from anemic mice using antibodies against 
TriMeK4, AcH3, AcH4, and Pol 11. Enrichment was determined relative to the inactive 
amylase gene by real-time PCR. Non-specific background was accounted for by dividing 
each value by the IgG ratio. Small horizontal black bars below the map of the human 0- 
globin locus indicate the positions of PCR amplification. 
LCR 3' HSS 
Figure 13: Analysis of post-translational histone modifications at .the P-globin gene in 
wild type and MBD2 null PYAC transgenic mice. ChIP assays were performed on 
splenocytes from anemic mice using antibodies against TriMeK4, AcH3, AcH4, and Pol 
11. Enrichment was determined relative to the inactive amylase gene by real-time PCR. 
The level of enrichment at the P-globin gene is >20-fold higher than at the y-globin gene. 
methyltransferases to the y-globin gene by RNA polymerase I1 in the absence of MBD2 
(Ng et al., 2003). As shown in Figure 6 and 10, the y-globin gene is expressed -10-fold 
higher in the wild-type 14.5 dpc fetal liver than in adult MBD2 null erythroid cells. As 
seen in Figure 14, the level of 
enrichment for TriMeK4 is -10-fold higher as well. This data indicates that the level of 
transcription is proportional to TriMeK4 enrichment and that the increase in y-globin 
mRNA is due to increased transcription of the gene. In addition, there is no significant 
difference between the level of AcH3 enrichment in wild-type versus MBD2 knock-out 
mice at the y-globin gene (Figure 12). Once again, the level of enrichment of this 
modification is much higher at the 0-globin gene (Figure 13). Loss of MBD2 leads to an 
increase in TriMeK4, AcH4, and Pol I1 levels at the y-globin gene promoter and 
increased TriMeK4 at the coding region but does not induce a similar increase in AcH3 
levels. 
Treatment of PYAC/MBD2+/+ mice with 5-azacytidine leads to a 10-1 5 fold 
induction of the y-globin gene versus mice treated with 1-acetyl-2-phenylhydrazine only 
(Figure 12) which is similar to the level of activation seen in PYACIMBD2-1- mice and in 
a different PYAC line treated with 5-azacytidine (Pace et al., 1994). To determine 
whether 5-azacytidine and MBD2 both induce y-globin mRNA via the same mechanism 
through DNA methylation, PYAClMBD2-1- mice were treated with 5-azacytidine. Blood 
was collected prior to 5-azacytidine treatment and again five days after treatment and 
analyzed by both RNase protection assay and quantitative real-time PCR (Figures 5 and 
15, respectively). 5-azacytidine only induces the y-globin by 2.5-fold (25-fold over wild- 
TriMeK4 Serum 
Figure 14: ChIP assay was performed on 14.5 dpc wild-type PYAC fetal livers. 
Chromatin was immunoprecipitated with anti-TriMeK4. The data is graphed relative to 
enrichments levels seen in adult MBD2+/+ and MBD2-1- PYAC transgenic mice. 
Figure 15: Analysis of 5-azacytidine mediated induction of the y-globin gene in 
MBD2+/+ and MBD2-1- PYAC transgenic mice. Induction of the y-globin gene by 5- 
azacytidne was determined relative to pre-treatment expression levels by real-time PCR. 
Treatment with 5-azacytinde results in a >lo-fold induction in MBD2+/+ mice while 
only a 2.5-fold induction is seen in MBD2-1- mice. 
type) in MBD2-I- mice. The lack of a synergistic effect (>1000-fold over wild-type) of 
MBD2 deficiency upon 5-azacytidine treatment strongly suggests that both are largely 
working through the same pathway, which is mediated by DNA methylation. This 
induction, while present, is sub-additive. However, the 2.5-fold induction may be due to 
the cytoxic effect of the drug or compensation by another methyl CpG binding protein. 
Furthermore, the activation of multiple pathways by 5-azacytidine is a possibility that 
cannot be ruled out. These alternate pathways may be the cause of the sub-additive 
induction. 
To determine the specificity of the MBD2 mediated y-globin gene repression, 
transgenic knock-out mice were made for a different MCBP, MeCP2. MeCP2 knock-out 
mice have a more severe phenotype than MBD2 knock-out mice characterized by 
uncoordinated gait, hind-limb collapsing, breathing irregularities, rapid weight loss, and 
death by day 54 (Guy et al., 2001). These symptoms are similar to the human 
neurological disorder Rett Syndrome, a disorder associated with MeCP2 loss or mutation. 
Transgenic knock-outs can be generated in one round of breeding by mating a male 
transgenic mouse with a hemizygous female. Multiple transgenic hemizygous females 
were obtained, however only one transgenic knock-out mouse was generated. Transgenic 
mice hemizygous for MeCP2 were made anemic and peripheral blood analyzed by RNase 
. protection assay. As shown in Figure 16, these adult mice do not express the human y- 
globin gene. Given that MeCP2 is X-linked, half of the blood cells should be null for 
MeCP2. These results indicate that loss of MeCP2 is not sufficient to induce expression 
of the y-globin gene. However, these results do not take into account the fact that other 
Figure 16: Expression of globin genes in MeCP2yI- and MeCP2+/- PYAC transgenic 
mice. The top panel shows an RPA for y-globin expression in MeCP2yI- and MeCP2+/- 
transgenic mice. The bottom panel shows a real-time PCR analysis of expression of 
globin genes in MeCP2yI- and MeCP2+/- @YAC transgenic mice. The level of expression 
of the ~y globin gene is >1000-fold less than 10.5 dpc yolk sac expression levels. 
factors expressed from other cells (ie cytokines) may be responsible for the induction of 
the y-globin gene in MBD2 null mice. One mouse transgenic for the PYAC and null for 
MeCP2 was generated. Peripheral blood was collected from this mouse without l-acetyl- 
2-phenylhydrazine treatment due to the frail condition of the mouse. RNA from 
peripheral blood was analyzed by RNase protection assay and real-time PCR. No y- 
globin RNA is expressed in this mouse (Figure 16). These results indicate that the effect 
seen due to loss of MBD2 is specific, because loss of MeCP2 does not generate the same 
phenotype. 
Discussion 
MBD2 is needed for complete suppression of the y-globin gene in PYAC 
transgenic mice. Loss of the protein leads to a level of expression from a single copy of 
the y-globin gene commensurate with PYAC mice treated with 5-azacytidine, -2% of the 
endogenous mouse a-globin RNA per gene copy. In addition, developmental silencing of 
the transgene is delayed in the absence of MBD2 as these mice express the y-globin gene 
at higher levels in 14.5 and 16.5dpc fetal livers. DNA methylation levels are modestly 
reduced while TriMeK4 levels are modestly increased around the y-globin gene in 
PYACIMBD2-I- mice. Treatment of PYACIMBD2-I- mice with 5-azacytidine leads to 
only a 2.5 fold induction of y-globin mRNA relative to PYAC mice treated with 5- 
azacytidine. 
The phenotype seen in MBD2 null PYAC transgenic mice appears to be due to 
increased transcription. The level of enrichment of TriMeK4 is proportional to 
transcriptional activity. As shown, there is an increase in TriMeK4 enrichment around the 
y-globin gene in MBD2 null transgenic mice. Thus, it seems unlikely that MBD2 loss 
leads to a stabilization of the y-globin mRNA or another non-transcriptional mechanism. 
Cytotoxic compounds such as 5-azacytidine, hydroxyurea, and araC have been proposed 
to increase fetal hemoglobin by inducing stress erythropoiesis (Stamatoyannopoulos, 
2005). In stress erythropoiesis, early differentiating erythroid cells that express the y- 
globin gene are accelerated through the differentiation pathway before they can fully 
silence the y-globin gene. Cytotoxic drugs result in increased erythropoiesis leading to 
increased production of y-globin mRNA. Thus, we investigated whether MBD2 mediates 
a stress erythropoiesis effect to induce y-globin mRNA expression. However, the red cell 
indices, including reticulocyte count, are not different between the two genotypes. 
Additionally, 1 -acetyl-2-phenylhydrazine induced hemolytic anemia fails to increase y- 
globin mRNA levels in MBD2-I- mice. It therefore seems unlikely that MBD2 is 
mediating a stress erythropoiesis effect to increase y-globin expression. However, it does 
not eliminate the possibility that MBD2 is somehow altering erythroid differentiation in a 
way that results in increased y-globin expression. In addition, the effect is very specific as 
loss of MeCP2 does not create the same phenotype nor are any endogenous mouse globin 
genes appreciably up-regulated in the absence of MBD2. Thus, it appears MBD2 is 
mediating a specific transcriptional up-regulation of the y-globin gene. 
Treatment of MBD2-I- mice with 5-azacytidine does not produce a synergistic 
increase in y-globin expression. However, there is a sub-additive increase in y-globin 
mRNA levels. There are four possible reasons to account for this effect. First, loss of 
MBD2 and 5-azacytidine are working along the same pathway via DNA methylation to 
repress y-globin transcription in adult m A C  transgenic mice. Given this, treatment with 
5-azacytidine in the MBD2 null background should not cause a further increase if both 
are working via the mechanism. This idea is supported by the similar level of y-globin 
mRNA after treatment with 5-azacytidine or in the absence of MBD2. Second, cytotoxic 
drugs such as hydroxyurea and AraC have been shown to increase y-globin mRNA levels 
in both huniaiis and baboons (Staniatoyannopoulos, 2005). Neither of these compounds 
affects DNA methylation, but they are hypothesized to exert their effect by stimulating 
stress erythropoiesis. The 2.5-fold induction seen may be the result of stress 
erythropoiesis due to the cytotoxic nature of 5-azacytidine. Third, drug treatment can lead 
to the activation or inactivation of many pathways. Treatment of 5-azacflidine in the 
MBD2 null background may be impacting a pathway outside of DNA methylation to 
create the 2.5-fold increase. Fourth, another MCBP may compensate for MBD2 loss. The 
loss of DNA methylation via 5-azacytidine treatment alleviates its contribution to y- 
globin repression and creates a 2.5-fold induction in expression. However, most of the 
known MCBPs can be eliminated as contributors. MeCP2 loss appeared to have no effect 
of y-globin mRNA levels. Kaiso binds to a specific site not found in .the y-globin gene. 
MBD3 does not bind to methylated DNA and MBD4 is a repair enzyme. As a result, 
MBDl is the only other known MCBP that could contribute to y-globin gene repression. 
Most MCBPs are thought to inhibit transcription by binding to promoters and 
recruiting transcriptional repression complexes. We have shown here only minor changes 
in DNA methylation status and post translational histone modifications around the y- 
globin gene in PYACIMBD2-I- mice. This is not completely surprising as the y-globin 
promoter does not possess a CpG island, a region of 200bp or more that have a CpG:GpC 
ratio of 0.6 (Antequera and Bird, 1993; Cross and Bird, 1995). In addition, there are no 
significant changes in global DNA methylation levels in MBD2-I- mice (Hendrich et al., 
200 1). Tl~us, MBD2 is not recruiting DNMT-activity to the y-globin gene. The modest 
decrease in DNA methylation levels seen in at the y-globin promoter region is likely due 
to increased transcription of the gene preventing DNMT-activity. While MBD2 has been 
shown to bind to as few as 2 CpG in vitro, this has not been shown in vivo (Kransdorf and 
Cinder, 2004). Thus it appears unlikely MBD2 binds directly to the y-globin promoter to 
mediate transcriptional repression of the y-globin gene for three reasons. First, the low 
CpG density is not an ideal binding site for MBD2. Second, MCBPs mediate their 
repressive effects through recruitment of transcriptional repression complexes that 
include HDACs. If MBD2 were recruited to the y-globin gene there should be an increase 
in both AcH3 and AcH4 in its absence. Instead, there is only enrichment for AcH4 at the 
promoter with no increase in AcH3 and no increase in AcH3 or AcH4 within the coding 
region. Third, work in cell hybrids shows the y-promoter region is unmethylated in the 
absence of transcription (Enver et al., 1988). The data here shows that y-globin 
expression stays high during development in the absence of MBD2, indicating MBD2 is 
necessary for silencing during development. If the promoter is still unmethylated at this 
time, MBD2 cannot be mediating its effect directly at the gene. Loss of MBD2 or 5-  
azacytidine treatment leads to increased expression of the y-globin gene in PYAC 
transgenic mice. Both appear to be working via the same mechanism that likely does not 
involve the y-globin promoter. MBD2 may be mediating its effect at a different location 
in the locus. The NuRD complex has recently been shown to be recruited to HS2 of the 
LCR in K562 cells (Mahajan et al., 2005). However, MBD2 was not shown to bind there, 
but MBD2 may be mediating its effect through a CpG dense region in the locus. The 6- 
globin locus does not possess a true CpG island, but it does contain pockets of increased 
CpG density. MBD2 binding at these sites may contribute to y-globin gene silencing. In 
addition, MBD2 may be regulating a gene in trans that when expressed increases y- 
globin gene expression. 
Many compounds currently available to treat patients with hemoglobinopathies 
are toxic and, in addition, the response to the agents is variable. Here we show that loss of 
MBD2 leads to expression of the normally silent y-globin gene in adult PYAC transgenic 
mice. Given the mild phenotype of MBD2 null mice, MBD2 may represent an attractive 
potential target for the treatment of /3-thalassemia or sickle cell anemia conditions in 
which increased y-globin gene expression has an ameliorating effect. 
Chapter 3: The Role of DNA Methylation and MBD2 on Human c-globin 
Regulation 
Introduction: 
The genes of the human P-globin locus are located on chromosome 11 in the order 
of their expression during development: 5' 6 ,  y, and /3 3'. During development, two 
switches occurs whereby the 5' globin gene (c or y) becomes silent and the gene directly 
3' becomes transcriptionally active. The exact mechanism of this process is not yet fully 
understood, however it has been show to involve many interactions between cis elements, 
erythroid specific trans factors, ubiquitous trans factors, and epigenetics. Transgenic 
mice with the human @-type globin genes have provided much insight into the 
mechanism(s) of globin gene switching. Mice containing the entire P-globin locus as a 
yeast artificial chromosome (PYAC) transgene show correct developmental expression 
and silencing of human globin genes (Gaensler et al., 1993; Peterson et al., 1993a; 
Peterson et al., 1993b; Zucker et al., 1983). In addition, mice transgenic with smaller 
globin gene constructs show similar developmental regulation (Stamatoyannopoulos and 
Grosveld, 2001). These transgenic studies have brought about the concept of competitive 
and autonomous silencing of globin genes. High level expression of globin genes is 
mediated by an enhancer located 5' of the human €-globin gene termed the locus control 
region (LCR). In the competition model, two globin genes compete .the enhancer activity 
of the LCR with one gene being highly expressed at the expense of the other. In the 
absence of another globin gene, the less competitive gene would still be expressed. In the 
case of autonon~ous ilencing, the gene would not be expressed even in the absence of 
other globin genes. The fetal y-globin gene has been shown to be regulated by a 
conibination of autonomous silencing and competition. This means y-globin transgenic 
mice in the absence of other globin genes decrease expression of the transgene during 
development, but cannot completely silence the gene without another globin gene present 
(Behringer et al., 1990; Dillon and Grosveld, 1991; Enver et al., 1989; Enver et al., 1990; 
Zucker et al., 1983). In the case of the c-globin transgenic mice, the gene is silenced in 
the absence of other globin genes and is thus autonomously silenced (Raich et al., 1990; 
Shih et al., 1990). 
The autonomous silencing of the €-globin gene has been shown to be mediated by 
many different factors binding to different locations around the gene. Both GATA-1 and 
YY 1 have been shown to bind to different regions of the €-globin gene and mediate 
transcriptional repression (Li et al., 1997; Raich et al., 1995). In addition, a complex was 
isolated that bound to two inverted direct repeats of a short motif analogous to DR-1 
binding sites for non-steroid nuclear hormone receptors in the region of .the CCAAT box 
(Tanimoto et al., 2000). Mutation of these repeats leads to expression of the €-globin gene 
in adult PYAC transgenic mice (Filipe et al., 1999; Tanimoto et al., 2000). A complex 
binding to this site, termed DRED, was found to contain the nuclear orphan receptors 
TR2 and TR4 (Tanabe et al., 2002). Thus, it appears many factors contribute to the 
autonomous silencing of the e-globin gene during development in transgenic mice. 
Globin genes have also been shown to be regulated by DNA methylation. The 
first correlation between transcriptional status and DNA methylation in vertebrates was 
seen in the avian globin locus (McGhee and Ginder, 1979). Further studies showed a 
similar correlation in other species and model systems (Atweh et al., 2003; Mavilio et al., 
1983; Shen and Maniatis, 1980; van der Ploeg and Flavell, 1980). The compound 5- 
azacytidine inhibits the enzyme DNA methyltransferase and leads to a decrease in DNA 
methylation levels. Treatment with 5-azacytidine has been shown to induce the 
expression of silenced embryonic and fetal P-type globin genes in many different model 
systems and in patient studies (Charache et al., 1983; DeSimone et al., 1982; Ginder et 
al., 1984; Ley et al., 1982; Ley et al., 1984; Pace et al., 1994; Zucker et al., 1983). A 
family of proteins has been identified that bind to methylated DNA and recruits 
transcriptional repression complexes, which include histone deacetylases (Feng and 
Zhang, 2001; Jones et al., 1998; Nan et al., 1993; Nan et al., 1998; Zucker et al., 1983). 
One member of this family is the methyl binding domain protein 2, MBD2. MBD2 has 
been shown to bind to a methylated p-globin construct as a large complex containing 
histone deacetylase 1 (Singal et al., 2002). In addition, short chain fatty acids, compounds 
known to inhibit histone deactylases among other functions, have been shown to induce 
the expression of embryonic and fetal P-type globin genes (Dempsey et al., 2003; 
Gabbianelli et al., 2000; Little et al., 1995; Marianna et al., 2001; Pace et al., 2002; 
Skarpidi et al., 2003; Stamatoyannopoulos and Grosveld, 2001 ; Zucker et al., 1983). 
Thus, in addition to factors mediating autonomous and competitive silencing, epigenetic 
modifications contribute to globin gene silencing. 
Herein we describe a role for both DNA methylation and MBD2 in mediating 
human €-globin silencing in adult transgenic mice. Transgenic mice containing 
continuous sequence from 5' of HS5 of the LCR through various lengths 3' of the E -  
globin polyA site correctly silence the transgene during development. This silencing is 
correlated with low levels of DNA methylation in the embryonic yolk sac and high levels 
in adult erythrocytes. Adult transgenic mice treated with 5-azacytidine express the 
normally silenced transgene. Furthermore, adult transgenic mice null for MBD2 also 
express the transgene. However, PYAC transgenic mice treated with 5-azacytidine or null 
for MBD2 express very low levels ;f the €-globin gene. These results indicate that 
competition may be necessary to silence the €-globin gene during 5-azacytidine treatment 
or in the absence of MBD2. 
Methods 
Generation of Transgenic Mice 
Transgenic mice were generated using two different constructs derived from the 
cosmid cosLCR6 (a generous gift from Frank Grosveld) that contain the entire sequence 
from 5' of HS5 of the LCR through 12 kb 3' of the human €-globin gene polyA site. A 28 
kb construct was generated by digesting cosLCR6 with Not1 and BstBI to release a 
fragment containing 4 kb of the 3' sequence. The constructs were run on a low-melting 
0.6% agarose gel and gel purified using the Bio 101 Gene Clean Spin Kit (Qbiogene). 
Constructs were then injected into fertilized eggs and implanted into pseudopregnant 
mothers to generate transgenic mice. Founders were determined by performing PCR on 
tail snipped DNA. Primers used to screen LCRE mice are shown in Table 7. Three lines 
were established for each construct. 
Copy Number Determination 
Genomic DNA was isolated from tails of positive mice. The DNA was digested 
with EcoRI and transferred to a nylon membrane. The blot was probed with a 600 bp 
fragment binding to the 3' end of the 3.7 kb portion of the human €-globin gene. The 
intensity of this band was compared to EcoRI digested negative mouse genomic DNA 
containing 2,5, 10,20, and 40 copies of the LCRE cosmid. 
Expression Profile of Mice 
The developmental regulation of the transgene in mice was determined by 
analyzing expression of the transgene at different developmental stages. Timed matings 
were performed as described in Chapter 2. RNA was extracted from 10.5 dpc yolk sacs, 
14.5 dpc fetal livers, and peripheral blood from adult anemic mice. RNase protection 
assays were used to analyze human €-globin mRNA expression. RPA probes protecting 
either exon 1 or exon 3 of the human e-globin gene were used for analysis. 
Generation of 28kb LCRdMBD2-I- Mice 
28kb LCRE mice from lines 1 and 2 were used to generate transgenic knock-out 
mice. As performed in Chapter 2, transgenic mice were bred with knock-out mice to 
generate hemizygous transgenic mice. These mice were bred with MBD2-I- mice to 
generate 28 kb LCRdMBD2-I- mice. Mice were screened for the presence of the 
transgene and absence of MBD2 by PCR of DNA from tail snips. Primers used to screen 
these mice are in Table 2 and 6. 
Treatment of Mice 
Mice were treated for two days with intraperitoneal injection of 1-acetyl- 
2-phenylhydrazine (10 mg/mL, Sigma) at a dose of 0.4 mgIl0g. On the third day, mice 
were treated with 5-azacytidine (0.5 mgImL, Sigma) at a dose of 2 mglkg for five days 
via intraperitoneal injection. 
Bisulfite Conversion 
EcoRI digested genomic DNA (1 pg) from adult anemic spleens and 10.5 dpc 
yolk sacs was diluted to 18 pL in water, boiled for 5 minutes and further denatured by 
treating with 2 pL fresh 2N NaOH at 37°C for 15 minutes. Sodium bisulfite solution was 
prepared by dissolviiig 1.9 g sodium bisulfite in 2 mL water and 400 pL 2N NaOH and 
dissolving 100 mg hydroquinone in 2 mL water. After mixing the solution, 1 mL of the 
hydroquinone solution was added to the sodium bisulfite solution. The solution pH was 
adjusted (if necessary) to pH 5.0. After denaturing the DNA, 130 pL of the bisulfite 
solution and 2 pg tRNA was added and the solution incubated in the dark for 4 hours at 
Primer Sequence 
El 1 
HBE 1202 
CTCCCCTTCACCGAATCTCATCC 
CTTAGCGCTTCCAGCTCTACTCCACTG 
Table 7: Primers used to screen LCRE transgenic mice. 
55" C. After incubation, add 5X volume of Buffer PB (Qiagen) and 30 pL 3M sodium 
acetate (pH 5.2) was added to the sample and the solution applied to a spin column 
containing 20 pL sodium acetate. Columns were spun at 10000 xg for 1 minute and the 
flow-through discarded. Column was washed with 700 pL Buffer PE and centrifuged 
again. The sample was eluted by adding 40 pL Elution Buffer, incubating at room 
temperature for 5 minutes, and centrifuging. The sample was desolfonated by addition of 
4.4 pL 3M NaOH and incubated at 3 7  C for 15 minutes. The sample was precipitated by 
addition of 28 pL 5 M ammonium acetate (pH 7.0), 2 pL pellet pain, 2 pg tRNA, and 180 
pL ethanol. Sample was then centrifuged for 10 minutes at 10500 rpm at 4' C. The final 
pellet was resuspended in 100 pL Elution Buffer. 
Single Nucleotide Primer Extension 
The DNA methylation status at a single CpGs was determined using single 
nucleotide primer extension (SNuPE). Primer extension was performed using nested PCR 
product from bisulfite converted DNA as a template. Primers were designed to 1 
nucleotide upstream of the CpG of interest. Primer extension was performed using CX-~*P 
dCTP or TTP (MP Biomedicals) in separate reactions. Primer extension was performed 
by heating at 95' C for 1 minute, annealing for 2 minutes, and extension at 72' C for 1 
minute. Only methylated CpGs will incorporate the dCTP while only unmethylated 
template will incorporate TTP. The reaction was terminated by adding RPA loading 
buffer. The products were analyzed on a 15% polyacrylamide gel after heating at 90' C 
for 5 minutes. The gel was exposed to X-Ray film and bands were quantitated using a 
phosphor-imager. The percentage of methylation at each site was determined by ,the 
following formula: intensity of dCTP band / (intensity of dCTP band + intensity of TTP 
band). The primers used for bisulfite specific PCR and SNuPE assay are listed in Table 8. 
Chromatin Irnmunoprecipitation 
Performed as described in Chapter 2. 
Real-time PCR 
Real-time PCR was performed as described in Chapter 2. The list of primers and 
probes used are listed in Table 5. 
Results 
Two constructs were used to generate transgenic mice. Both constructs contained 
the entire sequence from 5' of HS5 through 12 kb (36kb) and 4 kb (28kb) 3' of the 
human e-globin polyA site (Figure 17). Three independent transgenic lines of 36kb and 
28kb LCRE were established. Only 36kb LCRE line 1 and 28kb LCRE lines 1 and 2 were 
used in this work as 28kb LCRE line three appeared to have the transgene inserted in the 
Y-chromosome and similar results were seen with 36kb line 1 and both 28kb lines used. 
Previous work with similar human €-globin transgenic mice showed the transgene is 
highly expressed in the primitive erythroblasts of the 10.5 dpc yolk sac and appreciably 
silenced in the definitive cells of the 14.5 dpc fetal liver (Raich et al., 1990; Shih et al., 
1990). In addition, unlike transgenic mice containing various y-globin constructs, these 
PE - 19446 I GGAGAATAGGGGGTTAGAATTT 
Primer Sequence 
Bis-Prim2-194 17 GGAGAATAGGGGGTTAGAAT 
GAGAGGTAGTAGTATATATTTGTTTT 
Bis - Prim1 - 19667 
PE-19573 
Table 8: List of primers used for bisulfite specific PCR and SNuPE assay at the c-globin 
promoter region. 
CCCTTCATTCCCATACATTAAA 
GTTGAGGAGAAGGTTGT 
LCR 
LCR 
Figure 17: Constructs used to generate LCRE transgenic mice. The constructs only differ 
by the amount of sequence 3' of the c-globin polyA site: 12kb for the 36kb construct and 
4kb for the 28kb construct. 
mice showed complete autonomous silencing in the absence of any other human 0-globin 
gene. To determine whether the construct used to generate the 28kb and 36kb LCRE mice 
was autonomously silenced, timed matings were performed to analyze expression of the 
transgene in 10.5 dpc yolk sacs and 14.5 dpc fetal livers. All timed matings were 
performed by breeding a transgene positive male with a non-transgenic female. The 
presence of a vaginal plug was designated 0.5 dpc. Positive embryos were determined by 
screening placentas for the presence or absence of the transgene by PCR. RNA was 
isolated from transgene positive yolk sacs and fetal livers from 36kb LCRE line 1 and 
28kb LCRE lines 1 and 2 mice. Expression of the transgene was determined by RNase 
protection assay. As shown in Figure 18, the transgene is expressed in 10.5 dpc yolk sac 
and becomes silenced by 14.5 dpc. Thus, the 28kb and 36kb LCRE constructs show 
correct developmental silencing of the transgene, indicating the constructs contain all 
sequences necessary for autonomous silencing. Furthermore, transgene expression cannot 
be detected in the peripheral blood of anemic adult mice by RNase protection assay 
(Figure 19). 
The copy number of the transgenic mice was determined using Southern blotting. 
Genomic DNA was isolated from all lines and digested with EcoRI. A standard curve 
was generated using the LCRE cosmid at known concentrations mixed with non- 
transgenic genomic DNA. As shown in Figure 17, line 1 contains -10 copies of the 
transgene while line 2 contains -20 copies of the transgene. The 36kb LCRE line 1 mice 
contains -25 copies of the transgene (Figure 20). 
Figure 18: Developmental silencing of the human c-globin gene in LCRE transgenic 
mice. The transgene is expressed in the 10.5 dpc yolk sac erythroblasts and becomes 
nearly silent in the erythroid cells of the 14.5 dpc fetal liver. 
Figure 19: RPA analysis of human c-globin expression in adult LCRE transgenic treated 
with and without 5-azcytidine. No human €-globin mRNA is detected in adult 28kb and 
36kb LCRE transgenic mice peripheral blood. Treatment of both lines with 5-azacytidine 
induces expression of the normally silent transgene in adult mice peripheral blood. @=I- 
acetyl-2-phenylhydrazine, aza=5-azacytidine. 
Figure 20: Copy number determination of 28kb and 36kb LCRc transgenic mice. 
Southern blots were performed to determine the copy number using a probe located at the 
3' end of human c-globin gene. The copy number was by comparing signal intensity to a 
standard curve of known amounts of cosmid LCRc mixed with transgene negative 
genomic DNA. 
The inverse correlation between DNA methylation and transcriptional activity 
was first shown in vertebrates in the chicken 0-globin locus (McGhee and Ginder, 1979). 
In addition, a compound that inhibits the enzyme responsible for DNA methylation 
(DNMT) activates silenced embryonic and fetal globin genes in a variety of model 
systems, chickens, and patients (Ginder et al., 1984; Ley et al., 1982; Ley et al., 1984; 
Nienhuis et al., 1985; Pace et al., 1994). We sought to determine whether 5-azacytidine 
could activate the silenced human embryonic globin gene in the context of 28kb and 36kb 
LCRE transgenic mice. Adult mice made anemic via 1-acetyl-2-phenylhydrazine 
treatment fail to express the transgene as detem~ined by RNase protection assay. 
However, after a five day treatment regime with 5-azacytidine, adult 28kb and 36kb 
LCRE transgenic mice express the h ~ ~ m a n  c-globin gene (Figure 19 and 2 1). In the work 
done by Pace and colleagues, PYAC mice treated with 5-azacytidine express the y-globin 
gene, but expression of the human €-globin gene was not measured. Interestingly, we find 
that when treated with 5-azacytidine, adult PYAC transgenic mice fail to express the 
human €-globin gene as determined by RPA (Figure 22). However, when measured by 
real-time PCR, low levels are detectable (Figure 23). The 28kb and 36kb LCRE 
transgenic mice contain all necessary regulatory elements needed for autonomous 
transgene silencing. However, inhibition of DNA methylation is able to overcome these 
repressive elements. 
Given the ability of 5-azacytidine to overcome the autonomous silencing 
mechanisms of the human e-globin gene in 28kb and 36kb LCRE mice, we sought to look 
at the methylation status of CpGs around the promoter and proximal transcribed region of 
Figure 21: Real-time PCR analysis of human €-globin expression after treatment with 5- 
azacytidine and loss of MBD2 in LCRE transgenic mice. Wild type 28kb LCRE lines 1 
and 2 mice were treated with 5-azacytidine. Expression of the transgene was determined 
by real-time PCR using peripheral blood RNA from prior to treatment and after 
treatment. Peripheral blood RNA was also collected from both lines of mice in the 
MBD2+/- and MBD2-1- background. 
Figure 22: RPA analysis of human €-globin expression in m A C  transgenic mice treated 
with 5-azacytidine. In contrast, 5-azacytidine is able to induce expression of the y-globin 
gene in adult PYAC transgenic mice. RPA was performed on peripheral blood of mice 
treated with and without 5-azacytidine. 
Figure 23: Human €-globin expression in LCRc line 2 and PYAC transgenic mice. The 
top panel shows expression levels relative to 1 -acetyl-2-phenylhydrazine treatment only. 
The bottom panel represents the expression of the transgene relative to yolk sac 
expression levels. 
the transgene. Previous work in our laboratory has shown a correlation between DNA 
methylation in the promoter and proximal transcribed region of the chicken p-globin gene 
and the silencing of this gene during development (Ginder et al., 1984; Singal et al., 
1997; Singal et al., 2002). To examine the methylation status of 3 CpGs around the 
human €-globin promoter and proximal transcribed region, bisulfite conversion followed 
by single nucleotide primer extension was performed. The technique allows for the 
determination of the percentage of methylation at any CpG of interest in the genome. The 
level of methylation was compared at three different CpGs in 28kb LCRE line 2 
transgenic mice in 10.5 dpc yolk sac, adult anemic mice, and adult mice treated with 5- 
azacytidine. The promoter and proximal transcribed region in adult anemic mice is highly 
methylated (>90%) at all CpG sites tested (Figure 24). This result is in agreement with 
the idea that high levels of DNA methylation correspond to low levels of transcription. 
The transgene is highly expressed in the primitive erythroblasts of the 10.5 dpc yolk sac. 
At this time, the level of CpG methylation is much lower than in adult mice, -40% at 
each site tested. The genomic DNA used in this analysis came from total yolk sac tissue 
which contains epithelial cells in addition to erythroid cells. Epithelial cells do not 
express globin genes and are presumably highly methylated in the globin locus. In 
addition, erythroid cells have been found to only account for -1 1% of the total yolk sac 
population (Redmond and Lloyd, 2005). As a result, the level of DNA methylation seen 
in the 10.5 dpc yolk sac may in fact be much lower than 40%. Adult mice treated with 5- 
azacytidine show an intermediate level of methylation at each site (-80%). This 
correlates with expression data. While 5-azacytidine is able to induce expression of the 
Figure 24: MS-SNuPE analysis of DNA methylation levels around the €-globin promoter 
and proximal transcribed region. Bisuflite conversion was performed on genomic DNA 
from the splenocytes of anemic mice or 10.5 dpc yolk sac. After amplification by PCR, 
the DNA methylation levels were analyzed using MS-SNuPE at three sites around the E-  
globin promoter and proximal transcribed region in 28kb LCRE mice, mice treated with 
5-azacytidine and 10.5 dpc yolk sac erythroid cells. 
silenced transgene, it is expressed at a much lower level than in the 10.5 dpc yolk sac 
(Figure 23). The compound 5-azacytidine is highly toxic. While the dose administered to 
the mice is not fatal, it may be insufficient to produce high enough'levels of 
demethylation to recapitulate the level of expression seen in the yolk sac. In addition, 5- 
azacytidine is not specific for the P-globin locus and acts as a global inhibitor of DNA 
methylation. Hypomethylated DNA is associated with genetic instability and mice 
lacking DNMTs are embryonic lethal presumably due to this instability (Li et al., 1992; 
Okano et al., 1999). Cells hypomethylated due to 5-azacytidine treatment may undergo 
cell death due to the instability of genome leaving only moderately demethylated cells for 
the analysis. Finally, these mice have 20 copies of the transgene and the analysis does not 
discriminate between individual transgenes. Thus, the relatively low level of 
demethylation seen after 5-azacytidine treatment may be due to the number of copies of 
the transgene where only highly demethylated copies are expressing the transgene while 
methylated copies do not. This kind of variation on a cell-to-cell basis may account for 
the low level of demethylation seen after 5-azacytidine treatment. Taken together, these 
results show a positive correlation between the level of unmethylated CpGs around the 
human c-globin promoter and proximal transcribed region in 28 kb LCRE line 2 
transgenic mice and the level of transgene expression. 
Inhibition of DNA methylation leads to expression of the y-globin gene in PYAC 
transgenic mice and the human c-globin gene in 28 kb and 36 kb LCRc transgenic mice. 
Furthermore, loss of MBD2 leads to expression of the y-globin gene in PYAC transgenic 
mice. We sought to determine what impact MBD2 has on maintaining repression of the 
human c-globin gene in 28 kb LCRE transgenic mice. Mice null for MBD2 were bred 
with mice containing the 28 kb LCRE transgene. The resulting hemizygous mice were 
bred with MBD2 null mice again to generate transgenic knock-out mice. As was done 
previously, adult mice were made anemic to increase erythropoiesis. Blood was collected 
from the tail vein and analyzed by real time PCR. Adult 28kb LCRE transgenic mice null 
for MBD2 express the transgene at a level -1 6-45-fold over baseline (Figure 19). The 
variation in expression of the transgene between line 1 and line 2 may be due to position 
effects due to the location of transgene insertion that were not revealed during 5- 
azacytidine treatment. In addition, the higher copy number of the line 2 mice may be a 
rate limiting factor in transcription level. Mice containing the D A C  transgene and null 
for MBD2 express the y-globin gene and low levels of the human e-globin gene (Figure 
20). When standardizing expression to determine the fold induction due to 5-azacytidine 
treatment or loss of MBD2, the level of induction is similar in PYAC transgenic mice and 
28kb LCRE F2 mice (Figure 23). However, when calculating expression relative to yolk 
sac expression levels, the human €-globin gene is expressed 15-60-fold higher in LCRE 
transgenic mice versus PYAC transgenic mice (Figure 23). This is not surprising as loss 
of MBD2 leads to no enrichment in TriMeK4, AcH3, AcH4, and Pol I1 levels at the 
human €-globin gene promoter or coding regions (Figure 25). This result supports the 
notion that competition also plays a role in the silencing of the human €-globin gene. 
LCR 3' HSS 
Figure 25: Post-translational histone modification changes around the human €-globin 
gene promoter and proximal transcribed region in MBD2+/+ and MBD2-1- adult PYAC 
transgenic mice. Relative enrichment values were determined relative to the endogenous 
amylase gene to control for loading and IgG values to control for non-specific 
immunoprecipitation. 
Discussion 
Transgenic mice harboring constructs containing the entire sequence from 5' HS5 
through 4 kb 3' of the human €-globin gene correctly express and silence the gene during 
developnlent. Similar to other human c-globin transgenic mice, the mice generated here 
contain all necessary cis elements for autonomous silencing (Raich et al., 1990; Shih et 
al., 1990). Many factors have been shown to bind to the human €-globin promoter to 
mediate transcriptional repression and activity (Filipe et al., 1999; Li et al., 1998a; Li et 
al., 1997; Li et al., 1998b; Peters et al., 1993; Raich et al., 1995; Tanabe et al., 2002; 
Tanimoto et al., 2000; Wada-Kiyama et al., 1992). While studies have shown DNA 
methylation plays a causative role in the regulation of the chicken embryonic p-globin 
gene, little was known of the role of DNA methylation in human €-globin gene regulation 
(Ginder et al., 1984; Singal et al., 1997; Singal et al., 2002). Here, we show that 
inhibition of DNA methylation leads to expression of a silenced human e-globin 
transgene in adult mice. Furthermore, there is an inverse correlation between the level of 
DNA methylation around the c-globin promoter and proximal transcribed region and the 
level of expression of the transgene. Furthermore, loss of the methyl CpG binding 
protein, MBD2, leads to expression of the 28 kb LCRE transgene in adult mice. 
Initial studies with human €-globin transgenic mice indicated the gene does not 
require the presence of an additional human 0-type globin gene to become fully silenced 
during development. This was in contrast to the y-globin gene which requires the 
presence of an additional 0-type globin gene to become fully silenced in transgenic mice 
(Behringer et al., 1990; Dillon and Grosveld, 1991; Enver et al., 1989; Enver et al., 
1990). The y-globin gene is autoiiomously silenced, but requires competition for the 
upstream LCR enhancer for complete silencing. Until now, it was thought that 
competition was not needed for the complete silencing of the c-globin gene. We show 
that both 5-azacytidine and loss of MBD2 can induce expression of the silenced human E- 
globin transgene in LCRE transgenic mice. Using the same conditions, mice containing 
the entire 0-globin locus yeast artificial chromosome express 15-60-fold less c-globin 
RNA. The presence of additional 0-type globin genes inhibits expression of the human c- 
globin gene when PYAC transgenic mice lack MBD2 or are treated with 5-azacytidine. 
The other globin genes out-compete the c-globin gene for upstream LCR enhancer 
activity. 
The data presented here suggest the human c-globin gene is silenced by three 
mechanisms. First, and most likely strongest, is the autonomous silencing mediated by cis 
elements. This appears to be the primary mechanism by which the human c-globin gene 
is silenced. Disruption of cis elements leads to significant c-globin expression in adult 
mice (Raich et al., 1992; Raich et al., 1995; Tanimoto et al., 2000). In addition to 
elements located 5' of the human c-globin gene, we have shown 3' sequences may be 
involved. As shown here, 36kb and 28kb LCRE transgenic mice correctly express and 
silence the transgene during development. However, two lines of transgenic mice 
containing similar 5' sequence and only 100 bp 3' of the polyA site had an embryonic 
lethal phenotype (data not shown). The embryos were pale and small in size. We 
hypothesized the mice were suffering from an a-thalassemia due to overexpression of the 
€-globin chain that prevented normal hemoglobin tetramer formation. To test this 
hypothesis, a cosmid containing the entire sequence from 5' of HS5 through 100 bp 3' of 
the €-globin polyA site was proposed to be inserted into a specific chromosomal location 
in MEL cells. As a negative control, the 28kb construct was to be inserted into the same 
chromosomal location to prevent any position effects. Expression analysis was to be 
performed to determine whether lack of 3' sequence resulted in expression of the c-globin 
gene in adult erythroid cells. However, generation of these cells proved problematic. 
Using various transfection mechanisms, large cosmids were unable to be effectively 
transfected. Currently, alternative mechanisms are being proposed to determine whether 
the 3' silencer exists. 
Another layer of silencing is mediated by DNA methylation and MBD2. Loss of 
MBD2 or treatment with 5-azacytidine induces expression of the human c-globin gene in 
36kb and 28kb LCRE transgenic mice. However, low levels are also seen in PYAC 
transgenic mice under the same conditions. This revealed a third layer of silencing, 
namely competitive mechanism of human c-globin silencing as PYAC mice express 15- 
60-fold less c-globin mRNA than LCRc mice. The presence of other globin genes or 
additional down-steam sequences may prevent an effective interaction between the LCR 
enhancer and the c-globin gene in a >15-fold decrease in expression (Figure 26). 
However, the effect may be due to sequences present on the PYAC transgene rather than 
competition mediating this effect. Taken together, these results indicate the human E- 
globin gene is silenced by three mechanisms. We have shown significant expression 
when removing two of these mechanisms. An interesting study would be to combine 
elements of all three mechanisms to determine what fold repression each exerts on the E -  
globin gene. 
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Figure 26: Model of e-globin silencing in adult PYAC transgenic mice by sequences 
downstream of the €-gene. In the absence of other downstream sequences, loss of MBD2 
or treatment with 5-azacytidine allow for an effective interaction between the €-globin 
gene and the LCR enhancer leading to transcription of the transgene (top). In PYAC 
transgenic mice, the e-globin gene is expressed at a much lower level to disruption of .the 
enhancer interaction by other globin genes or downstream sequences (middle and 
bottom). 
Chapter 4: Mechanism of MBD2 Mediated Repression of the y-globin Gene 
Introduction 
Adult transgenic mice null for MBD2 express silenced embryonic and fetal globin 
genes. The level of induction of the y-globin gene in PYACIMBD2-I- mice is similar to 
the level seen in PYAC mice treated with the DNA methyltransferase inhibitor 5- 
azacytidine. In addition, treatment of PYACIMBD2-I- with 5-azacytidine does not 
produce an additive induction of y-globin RNA relative to treatment of wild type PYAC 
mice. These results indicate that MBD2 and 5-azacytidine work via the same mechanism 
to induce globin gene expression. In addition to the work presented here, previous work 
has shown treatment with 5-azacytidine leads to hypomethylation around the globin gene 
promoters and a concomitant increase in embryonic or fetal globin transcription (Ginder 
et al., 1984; Ley et al., 1983; Ley et al., 1984; Zucker et al., 1983). With the discovery of 
proteins that specifically bind to niethylated DNA and recruit transcriptional repression 
complexes, it seemed a likely hypothesis that these proteins were mediating the 
repressive effect seen on genes up-regulated upon DNMT inhibition by binding to 
methylated CpGs around the promoter and inhibiting transcription. However, only a 
handful of genes have been shown to be bound by MCBPs in vivo in non-cancerous cells 
(Chen et al., 2003; Hutchins et al., 2002; Klose et al., 2005; Kransdorf and Ginder, 2004; 
Martinowich et al., 2003). The y-globin gene has been reported to be regulated by many 
mechanisms including by multiple signaling pathways and by epigenetic modifications 
(Bhanu et al., 2004; Bhanu et al., 2005; Pace et al., 2003). Thus, MBD2 mediated 
transcriptional repression of the E- and y-globin genes in adult LCRE and PYAC 
transgenic may be due to direct recruitment of MBD2 to the E- or y-globin promoter, or 
via a cell signaling pathway or both. Therefore, we sought to determine whether MBD2 
binds the E- or y-globin promoter in vivo and what gene(s) were aberrantly expressed in 
MBD2 null mice that mediated these effects. To do this, chromatin immunoprecipitation 
assays were performed to locate where MBD2 was binding to mediate transcriptional 
repression of the E-  and y-globin genes. Microarray analysis was performed on MBD2+/+ 
and MBD2-1- mice to determine what genes are differentially expressed in adult erythroid 
cells. The data from the microarray was further analyzed using a pathway analysis 
program to determine what pathways were differentially impacted due to the loss of 
MBD2. 
Methods 
Chromatin Irnmunoprecipitation 
Chromatin immunoprecipitation was performed as described in Chapter 2 with the 
following modifications. Chromatin was crosslinked with 1% formaldehyde for 10 
minutes at room temperature. Sonication was performed 8x instead of 6x. Chromatin was 
washed three times with low salt buffer and one time with medium salt buffer (equal 
parts high salt and low salt buffer). Immunoprecipitations were performed with anti- 
MBD2 (Upstate), anti-MBD213 (Upstate), ant-MTA2 (Santa Cruz), goat IgG (Santa 
Cruz), sheep IgG, and protein G salmon sperm agarose beads. DNA was analyzed using 
real-time PCR and SYBR Green chemistry. Primers used for real-time PCR analysis are 
listed in Table 9. 
Lower stringency washes were used because DNA binding proteins that are more 
difficult to ChIP than histones owing to lower abundance. Thus, to account for increased 
non-specific pull-down, enrichment was determined with the following formula: 
Sample-(gene boundlinput)/(amylase boundlinput) 
IgG-(gene bound/input)/(amylase boundlinput) 
Microarray Analysis 
Four wild type mice and four MBD2-1- mice were treated with l-acetyl-2- 
phenylhydrazine for two days. Spleens were harvested on the fifth day and RNA isolated 
using Trizol. The RNA was treated with DNase I using the Turbo DNase kit (Ambion). 
The RNA was further cleaned and concentrated using the RNeasy MinElute Cleanup kit 
(Qiagen). The RNA was eluted in DEPC-treated water to which 1 pL of SuperRNasin 
was added per 40 pL water. RNA purity was judged by the ratio of absorbance at 260 and 
280 nm (A260 / A2*0) and 260 and 270 nm (A260 1 A270). In addition, RNA, cDNA, and 
cRNA integrity were assessed by running 1 pL of every sample in RNA 6000 Nano or 
Table 9: List of primers used for real-time PCR for ChP assays in Chapter 4. 
Primer 
Ugt8-F-1574 
Ugt8ChIP-Probe 
Ugt8-R- 167 1 
Gammaprom-ChP-F 
Gammaprom-ChP-Probe 
Gammaprom-ChP-R 
-3.4GATA2 F
-3.4GATA2 R
Sequence 
TTAGAGCTCTGAAGGGCATGTGGA 
6famTGCTCTGCGTCTCCCAAACTCAAGAAtamra 
TGTGCTAATTCCTCCCGCAACAGA 
CCTTGCCTTGACCAATAGCCTTGA 
6famACAAGGCTACTATCACAAGCCTGTGGtamra 
TTCCAGAAGCGAGTGTGTGGAACT 
TCCATCCAGCAGCTTTAGGAA 
GGGTTCGAAGCCACTCCAA 
Pico LabChips on the 21 00 Bioanalyzer (Agilent) depending on the RNA concentration, 
according to manufacturers protocol. RNA (5 pg) was reverse transcribed to cDNA 
using a 24-mer oligodeoxythymidylic acid primer with a T7 RNA polymerase promoter 
sited added the 3' end of the T7-olidgo(dT) using the Superscript cDNA Synthesis 
Systems (Life Technologies). In vitro transcription was performed using the Enzo 
BioArray High Yield RNA Transcript Labeling kit (Enzo) to produce biotin-labeled 
cRNA. For each sample, 20 pg of the cRNA product was fragmented and hybridized for 
18-20 h onto an Affymetrix Genechip 430A 2.0 microarray (Affymetrix). Each 
microarray contains 45,000 probes sets analyzing the expression of over 39,000 different 
transcripts where one transcript is generally interrogated by more than one probe set. 
Each probe set contains probes that either perfectly match (PM) the sequence in a 
segment of the target gene or contain a single mismatched (MM) nucleotide in the middle 
position of the corresponding perfectly matched probe. The intensity difference of PM 
probes and MM probes is used to make detection calls which determine whether the 
transcript of a gene is detected or undetected. Each microarray was washed and stained 
with streptavidin-phycoerythrin and scanned at a 6 pm resolution with the Agilent 
G2500A Technologies Gene Array scanner (Agilent Technologies) according to the 
GeneChip Expression Analysis Technical Manual procedures (Affymetrix). 
After scanning, the scaling factor, the noise (RawQ) value for a given probe array 
hybridization, the percentage of probe sets declared "Present" (%P) by the detection call 
algorithm, the 3'15' ratios of the signal intensity values for two house-keeping genes 
(GAPDH and 0-actin), and the presence or absence call for the ribosomal RNAs 18s and 
28s were determined for quality control purposes. 
For every probe set, normalization, background subtraction, and expression 
summaries were calculated using three different methods. First the Microarray Suite 5.0 
method was used to obtain probe set summaries. Model-based expression indices were 
calculated by use of a multiplicative model to account for probe affinity effects in 
calculating probe set expression summaries. Lastly, the multiarray average method was 
used. This method uses quantile nornlalization followed by a median polish to remove 
probe affinity effects when calculating probe set summaries. Only genes significantly 
changed using all three methods were used for further analysis. All microarray studies 
were performed by Dr. Cathrine Dumur in the Virginia Commonwealth University 
Department of Pathology. 
Pathway Analysis 
To determine whether the differentially expressed genes in the microarray were 
impacting cell signaling pathway(s), the gene list was analyzed using the Ingenuity 
Pathway Analysis (IPA) program (Ingenuity Systems). Two sets of gene lists were 
analyzed using different P-values, <0.005 and <0.01. This program uses the Ingenuity 
Pathways Knowledge Base (IPKB) to provide insights into observed gene expression 
changes across biological samples. The input to this application corresponds to a user 
generated dataset file containing differentially expressed genes. Genes of interest to the 
user, that are also known to directly (or indirectly) interact with other genes in the IPKB, 
are called Focus Genes and are used to identify molecular networks that indicate how 
these genes may influence each other. IPA dynamically computes a large "global" 
molecular network based on hundreds of thousands of curated direct and indirect physical 
and functional interactions between orthologous mammalian genes from the published, 
peer-reviewed content in Ingenuity's Knowledge Base. 
CpG Island Determination 
The genornic DNA sequence of up-regulated genes from microarray analysis were 
obtained from the Mouse Genome Inforniatics web site (http://www.informatics.jax.org/). 
This sequence was analyzed with the CpG Island Searcher program using default 
parameters (http://cpgislands.usc.edu/). 
Real-Time PCR 
Candidate genes from microarray analysis were analyzed using real-time PCR to 
confirm differences in expression between wild-type and knock-out splenocytes. 
Candidate gene were chosen based on the level of significance (P-value <0.01) and 
presence in a hematological pathway. RNA from six of the eight mice analyzed in the 
microarray was first reverse transcribed using Script (Bio-Rad). Candidate genes were 
analyzed using pre-designed Taqman probes sets (Applied Biosystems) or SYBR Green 
chemistry with pre-designed primer sets (Wang and Seed, 2003). All values were 
standardized using mouse cyclophilin A as an internal control. Primers used for real-time 
PCR analysis are located in Table 10. 
Table 10: Primers used for real-time PCR validation of microarray results and 
confirmation of MBD2 knock-down. 
Primer 
BAF57-114-F 
BAF57-114-R 
Ugt8-121-F 
Ugt8-121-R 
ROG- 10 1 -F 
ROG-101-R 
mCyclophilinA-F 
mCyclophilinA-R 
Jund 1 
MAPK3 
Sequence 
AAAAGACCATCTTATGCCCCAC 
CCTGTAGTTGTTGTAGGCGAG 
ACTCCATATTTCATGCTCCTGTG 
AGGCCGATGCTAGTGTCTTGA 
GCTCTGAGAGAGGACTTGGGA 
TGCTTTATGCTTGTGTGACATCT 
GAGCTGTTTGCAGACAAAGTTC 
CCCTGGCACATGAATCCTGG 
ABI Part #: Mm01343 193-sl 
ABI Part #: Mm01973540 - gl 
Results 
The promoter region of the y-globin gene does not contain a CpG island. In fact, 
no region of .the promoter contains more than 4 CpGs within a 70 bp span. Preliminary 
C h P  results indicated MBD2 was not bound to the promoter region of the y-globin gene, 
but was slightly enriched in the 5' region of the GATA2 gene (Figure 27). Taken 
together, these results led us to believe MBD2 was not mediating its repressive effect by 
binding to the y-globin promoter region. Studies in cell culture lines and primary human 
erythroid cells have shown cell signaling pathways play a role in y-globin transcriptional 
regulation (Bhanu et al., 2004; Bhanu et al., 2005; Ikuta et al., 2001; Pace et al., 2003). 
Thus, we postulated MBD2 may be differentially regulating a factor needed for y-globin 
activation directly or by regulating a factor in a signaling pathway necessary for y-globin 
transcriptional activation. To determine which gene(s) were involved, microarray 
analysis was performed. Four wild-type and four MBD2 knock-out mice were made 
anemic by 1-acetyl-2-phenylhydrazine treatment. Spleens were harvested on the fifth or 
seventh day and RNA isolated. After amplification, the RNA was hybridized to the 
Affymetrix 430A2.0 mouse microarray chip. ANOVA analysis on each probe set 
identified -25 genes upregulated significantly (p<0.005) in MBD2-1- erythroblasts and 
266 genes differentially regulated using significant but less stringent analysis (p<0.01) 
(Table 11). Upon initial observation, there was no known erythroid specific factor that 
was up- or down-regulated in MBD2-/- erythroblasts. However, almost every gene 
upregulated in MBD2-/- cells contained a CpG island (Table 12) using the default 
settings of the CpG Island Searcher Program (http://cpgislands.usc.edu/). 
LC R 3' HSS 
Figure 27: Determining in vivo binding of MBD2 using the ChIP assay. ChIP assays were 
performed using anti-MBD2, ant-MTA2, and sheep and goat IgG antibodies. DNA was 
analyzed using real-time PCR at the human E -  and y-globin promoters, a weak CpG 
island between the y-globin and 6-globin genes, the human 0-globin coding region, the 
Ugt8 gene CpG island, the ROG gene CpG island, and the upstream region of the 
GATA2 gene. Data was normalized to endogenous amylase levels to account for loading 
errors and IgG to account for non-specific pull-downs. 
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Gene 
methyl-CpG binding domain protein 2 
inositol polyphosphate-5-phosphatase B 
tripartite motif protein 30-like 
apolipoprotein B editing complex 3 
3-phosphoglycerate dehydrogenase 
RIKEN cDNA 26 10034N03 gene 
histoconlpatibility 28 
tripartite motif protein 12 
tyrosyl-tRNA synthetase 
RAB3A interacting protein 
RAP2B, member of RAS oncogene family 
expressed sequence C79248 
UDP-glucuronosyltransferase 8 
tropomodulin 4 
G kinase anchoring protein 1 
RIKEN cDNA 2410026K10 gene 
LanC (bacterial lantibiotic synthetase component C)-like 1 
16 days neonate thymus cDNA, RIKEN full-length 
enriched library, clone:A130032A08 product: 
unclassifiable, full insert sequence 
cell division cycle associated 3 
cDNA sequence BC004690 
tripartite motif protein 34 
& 
cysteine-rich protein 1 (intestinal) 
hairylenhancer-of-split related with YRPW motif 2 
solute carrier family 35 (UDP-glucuronic acid/UDP- 
N-acetylgalactosamine dual transporter), member Dl  
stearoyl-Coenzyme A desaturase 2 
interferon-induced protein 44 
RIKEN cDNA 261 0034N03 gene 
3-hydroxyisobutyryl-Coenzyme A hydrolase 
MAS 1 oncogene 
receptor-like tyrosine kinase 
RIKEN cDNA 6720467C03 gene 
transcriptional regulator, SIN3B (yeast) 
receptor-like tyrosine kinase 
2'-5' oligoadenylate synthetase 1D //I 2'-5' oligoadenylate 
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1.89 
-1.36 
-2.58 
-1.08 
1.15 
-1.36 
1.12 
-1.65 
1.33 
-1.26 
-1.74 
-2.68 
1.87 
2.02 
-1.22 
1.35 
-1.21 
1.50 
-1.18 
1.41 
1.17 
-1.20 
1.12 
synthetase 1E 
RIKEN cDNA 201 0002A20 gene 
pan hematopoietic expression 
RIKEN cDNA 25 1001 5F01 gene 
zinc finger, FYVE domain containing 21 
zinc finger, FYVE domain containing 2 1 
RIKEN cDNA 25 10048K03 gene 
expressed sequence A1447904 
RIKEN cDNA 2300006M17 gene 
cDNA sequence BC028528 
RIKEN cDNA 9 130208E07 gene 
histidyl-tRNA synthetase 
expressed sequence AW060207 
polymerase (DNA directed), delta 2, regulatory subunit 
RIKEN cDNA 1810010014 gene 
suppressor of Ty 16 homolog (S. cerevisiae) 
thioredoxin 2 
methyl-CpG binding domain protein 2 
transcription factor 7-like 2, T-cell specific, HMG-box 
deleted in polyposis 1 
RNA-binding region (RNP1, RRM) containing 2 
RIKEN cDNA 170000 1 E 16 gene 
signal recognition particle receptor, B subunit 
glycyl-tRNA synthetase 
solute carrier faniily 39 (zinc transporter), member 9 
serine hydroxymethyl transferase 2 (mitochondrial) 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 19 /// 
RIKEN cDNA 28 10457M08 gene 
3-ketoacyl-CoA thiolase B 
RIKEN cDNA 1 8 100 100  14 gene 
Diabetic nephropathy-related gene 1 mRNA, partial sequence 
phytanoyl-CoA hydroxylase 
GTP cyclohydrolase 1 
cell division cycle 26 
5-azacytidine induced gene 2 
RIKEN cDNA 8430432M10 gene 
cDNA sequence BC002199 
expressed sequence 2 embryonic lethal 
cardiac lineage protein 1 
RIKEN cDNA 4932432K03 gene 
hemoglobin alpha, adult chain 1 
RIKEN cDNA 1 1 10028N05 gene 
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1.24 
-1.61 
1.64 
1.55 
-1.18 
-1.44 
- 
-2.92 
1.19 
myelin basic protein 
kinesin family member 5B 
tripartite motif protein 34 
membrane-associated protein 17 
RIKEN cDNA C730025P13 gene 
expressed sequence AU040320 
thioredoxin 2 
DNA segment, Chr 7, ERATO Doi 760, expressed 
coiled-coil-helix-coiled-coil-helix domain containing 5 
RIKEN cDNA 3 1 10007P09 gene 
RIKEN cDNA 1 1 10053F04 gene 
RIKEN cDNA 26 1000 1 E 17 gene 
runt related transcription factor 1 
cDNA sequence ~C053917  
ROD1 regulator of differentiation 1 (S. pombe) 
DNA-damage inducible transcript 3 
epidermal growth factor-containing fibulin-like extracellular 
matrix protein 1 
solute carrier family 1 (glutamatelneutral amino acid 
transporter), member 4 
secreted acidic cysteine rich glycoprotein 
tyrosine kinase, non-receptor, 1 
spermatogenesis associated 13 
glutathione S-transferase omega 1 
tripartite motif protein 24 
RIKEN cDNA E030006K04 gene 
ubiquitin carboxyl-terminal esterase L5 
regulatory factor X-associated ankyrin-containing protein 
restin (Reed-Steinberg cell-expressed 
intermediate filament-associated protein) 
leucine-rich repeats and immunoglobulin-like domains 1 
RIKEN cDNA 23 10057G13 gene 
cDNA sequence BC019537 
crumbs homolog 1 (Drosophila) 
casein kinase 1, alpha 1 
ubiquitin C 
DNA segment, Chr 8, ERATO Doi 354, expressed 
RIKEN cDNA 2610034N03 gene 
KDEL (Lys-Asp-Glu-Leu) containing 1 
RIKEN cDNA 2410026K10 gene 
coproporphyrinogen oxidase 
thioredoxin 2 
1.26 
-1.37 
-1.31 
-2.48 
1.37 
1.44 
-1.16 
1.39 
6.42 
-1.28 
-1.96 
-1.31 
1.28 
1.46 
-1.53 
-1.18 
-1.49 
1.44 
-1.32 
1.20 
-1.74 
1.29 
-2.01 
1.22 
1.17 
2.03 
-1 -06 
1.16 
1.40 
1.17 
-1.83 
-1.21 
-1.65 
1.79 
1.14 
1.64 
-1.31 
1.32 
1.29 
zinc finger protein X-linked 
RIKEN cDNA 1200006F02 gene 
sphingosine kinase 1 
RlKEN cDNA 9830147J24 gene 
SWUSNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily e, member 1 
HIV- 1 Rev binding protein 
Ceruloplasmin 
Rho guanine nucleotide exchange factor (GEF) 12 
microfibrillar-associated protein 1 
cDNA sequence BC011467 
tripartite motif protein 34 
RIKEN cDNA 3 1 10005G23 gene 
2'-5' oligoadenylate synthetase 1E 
SUMOIsentrin specific protease 2 
membrane-associated protein 17 
RIKEN cDNA 11 10014L17 gene 
phosphoinositide-3-kinase, class 3 
SUMOIsentrin specific protease 2 
diptheria toxin resistance protein required for 
diphthamide biosynthesis (Saccharomyces)-like 1 
protein phosphatase 2a, catalytic subunit, beta isoform 
deanlinase domain containing 1 
interferon alpha responsive gene 
growth arrest and DNA-damage-inducible 45 alpha 
spectrin beta 2 
rabaptin, RAE3 GTPase biildiilg effector protein 1 
Clone L2MZB- 13.5 immui~oglobulin heavy chain variable 
region mRNA, partial cds 
DnaJ (Hsp40) homolog, subfamily C, member 4 
phosphate cytidylyltransferase 2, ethanolamine 
TRAF family member-associated Nf-kappa B activator 
protein phosphatase 1, catalytic subunit, gamma isoform 
RIKEN cDNA 23 10009N05 gene 
F-box only protein 3 1 
zinc finger protein 3 86 (Kruppel-like) 
cDNA sequence BC008 163 
casein kinase 11, alpha 2, polypeptide 
CCR4 carbon catabolite repression 4-like (S. cerevisiae) 
phosphomannomutase 1 
adaptor-related protein complex 3, mu 1 subunit 
UDP-glucose pyrophosphorylase 2 
-1.80 
1.55 
1.28 
1.58 
-3.40 
1.25 
1.27 
1.40 
-1.12 
1.41 
1.43 
1.08 
4.32 
-1.09 
-2.40 
2.40 
1.18 
1.34 
1.93 
1.20 
1.63 
1.68 
-1.14 
1.64 
-1.18 
1.22 
1.47 
1.79 
1.22 
1.31 
-1.07 
1.47 
1.20 
-2.61 
1.34 
-1 -25 
1.44 
-1 -44 
1.25 
1.53 
ubiquitin C 
low density lipoprotein receptor-related protein associated protein 1 
Sjogren syndrome antigen B 
Similar to PCAF acetyltransferase; p300lCBP-associated 
factor (LOC330129), mRNA 
guanylate nucleotide binding protein 2 
RIKEN cDNA 6820402020 gene 
zinc finger, CW-type with coiled-coil domain 3 
eukaryotic translation initiation factor 3, subunit 1 alpha 
Similar to ubiquitin A-52 residue ribosomal protein fusion 
product 1 (LOC383341), mRNA 
Janus kinase 1 
Ninein 
RIKEN cDNA 63305 12M04 gene 
microfibrillar-associated protein 1 
nuclear receptor subfamily 2, group C, member 1 
3-phosphoglycerate dehydrogenase 
microfibrillar-associated protein 1 
growth factor receptor bound protein 2-associated protein I 
ribulose-5-pliosphate-3-epimerase 
cyclin M2 
Rab geranylgeranyl transferase, a subunit 
GTP cyclohydrolase 1 
lipocalin 7 
Era (G-protein)-like 1 (E. coli) 
camitine acetyltransferase 
nurim (nuclear envelope membrane protein) 
RIKEN cDNA 1810017G16 gene 
RIKEN cDNA 2700084L22 gene 
adaptor-related protein complex 3, mu 1 subunit 
RIKEN cDNA 23 10020A2 1 gene 
RIKEN cDNA 26 10020H 15 gene 
PYD and CARD domain containing 
DNA segment, Chr 16, ERATO Doi 480, expressed 
pregnancy-specific glycoprotein 23 
purine-nucleoside phosphorylase 
topoisomerase (DNA) I 
Clone IMAGE:3983419, mRNA 
expressed sequence C78339 
nucleotide binding protein 2 
Itchy 
RIKEN cDNA 4833415E20 gene 
-1.53 
1.80 
1.53 
1.3 1 
-1.50 
-3.13 
1.42 
1.18 
1.38 
-1.35 
-1.30 
-2.46 
-1.30 
-1.36 
-1.31 
1.46 
- 
-1.18 
1.67 
-2.87 
-1.19 
1.57 
1.19 
1.52 
1.31 
1.41 
2.11 
-1.41 
1.99 
1.30 
1.11 
-1.60 
1.30 
1.26 
1.22 
1.31 
1.33 
1.22 
-1.61 
1.12 
1.33 
1.15 
fibulin 5 
peptidase 4 
tripartite motif protein 25 
nudix (nucleoside diphosphate linked moiety X)-type motif 4 
synaptogyrin 1 
purine-nucleoside phosphorylase 
niban protein 
ribonucleotide reductase M2 
HIV- 1 Rev binding protein 
scavenger receptor class B, member 2 
RIKEN cDNA D230019K24 gene 
lymphocyte antigen 6 complex, locus A 
eukaryotic translation initiation factor 3, subunit 8 
Jun proto-oncogene related gene d l  
palmitoyl-protein thioesterase 2 
procollagen, type V, alpha 1 
RIKEN cDNA 1 1 10035L05 gene 
aminopeptidase puromycin sensitive 
CD5 antigen-like 
RIKEN cDNA 12000 14P03 gene 
hypothetical protein A1 30072507 
RIKEN cDNA 23 10037124 gene 
vesicle-associated membrane protein 3 
nuclear transport factor 2 
platelet-activating factor acetylhydrolase, isoform 1 b, alpha2 subunit 
repressor of GATA 
solute carrier family 12, member 2 
glioblastoma amplified sequence 
protein phosphatase 4, regulatory subunit 2 
solute carrier family 13 (sodium-dependent 
dicarboxylate transporter), member 3 
DnaJ (Hsp40) homolog, subfamily D, member 1 
UDP-N-acetylglucosamine pyrophosphorylase 1 
protein kinase, lysine deficient 1 
SUMO 1 Isentrin specific protease 1 
RIKEN cDNA 3300001P08 gene 
zinc finger, CW-type with coiled-coil domain 3 
interferon (alpha and beta) receptor 2 
pyruvate dehydrogenase kinase, isoenzyme 1 
cellular nucleic acid binding protein 1 
ubiquitin-conjugating enzyme E2, J1 
LIM domain only 7 
-1.72 
1.26 
1.37 
serine (or cysteine) proteinase inhibitor, clade G, member 1 
RIKEN cDNA 28 1005 5E05 gene 
adducin 1 (alpha) 
Table 11 : List of all genes differentially regulated in MBD2-1- mice from microarray 
Analysis at P<0.01. 
UDP-glucuronosyltransferase 8 
Kinesin family member 24 
Gene 
Solute carrier family 35 
GTP cyclohydrolase 1 
Gene Symbol 
Slc35dl 
Gch 1 
Regulator of differentiation 1 I Rod1 I 
RAB3A interacting protein I 
Inositol polyphosphate-5-phosphatase B 
Cysteine-rich protein 1 
Transcription factor 7-like 2 
Recptor-like tyrosine kinase 
RAB3A interacting protein 
Procollagen, type V, alpha 1 
Inpp5b 
Crip 1 
Tcfll2 
R Y ~  
Crystallin, lamda 1 
SUMOIsentrin specific protease 2 
I 
Table 12: List of genes significantly up-regulated in the absence of MBD2 possessing a 
CpG island (P<0.005). 
No gene from the high specificity list (p<0.005) appeared to be an erythroid 
specific factor. Therefore, we analyzed both lists using the Ingenuity Pathway Analysis 
(IPA) program to discern the impact of MBD2 on known cellular pathways. This 
program uses the Ingenuity Pathways Knowledge Base (IPKB) to provide insights into 
observed gene expression changes across biological samples. The input to this application 
corresponds to a user generated dataset file containing differentially expressed genes. 
Genes of interest to the user, that are also known to directly (or indirectly) interact with 
other genes in the IPKB, are called Focus Genes and are used to identify molecular 
networks that indicate how these genes may influence each other. IPA dynamically 
computes a large "global" molecular network based on hundreds of thousands of curated 
direct and indirect physical and functional interactions between orthologous mammalian 
genes from the published, peer-reviewed content in Ingenuity's Knowledge Base. 
Analysis of both data sets (P<0.005 and 0.01) identified several genes in known 
hematologic pathways (Figure 28). We analyzed four genes by real-time PCR we thought 
may represent candidate genes from these pathways: mitogen activated protein kinase 3 
(MAPK3), zinc finger and BTB domain containing protein 32 (TZFP), jun proto- 
oncogene related gene d l  (JunDl), and SwiISNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily e, member i (Baf57). As a positive control, 
the gene having the highest fold difference between knock-out and wild type cells, UDP 
galactoyltransferase 8A (Ugt8), was also analyzed. As shown in Figure 29, only TZFP 
and Ugt8 were upregulated in MBD2 null mice. This result indicates the importance of 
confirming the results of microarray analysis especially 
Figure 28: Hematological pathway identified by Ingenuity Pathway Analysis software. 
Figure 29: Validation of potential candidate genes by real-time PCR. The results shown 
are the average of three mice of each phenotype. The RNA used for this validation is the 
same used for the microarray analysis. 
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when lowering the P-value for analysis purposes. TZFP was found to be increased >20- 
fold in MBD2-I- erythroblasts. TZFP is also known as repressor of GATA (ROG), PLZF- 
like zinc finger protein (PZLP) and Fanconi anemia zinc finger (FAZF). TZFP is a POZ 
(POZ and Kriippel) protein containing three C2-H2 Kriippel-type zinc finger domains and 
has been shown to heterodimerize with FANC-C and PLZF and is therefore proposed to 
play a role in Fanconi's anemia and acute promyelocytic leukemia (APL) (Hoatlin et al., 
1999). In addition, TZFP has been shown to interact with GATA-2, although the effect of 
the interaction has not been determined (Tsuzuki and Enver, 2002). GATA-2 has been 
shown to upregulate y-globin expression in K562 cells (Ikonomi et al., 2000). 
Interestingly, a CpG island is located just 3' of the TZFP gene and just upstream of the 
MLL2 gene. Taken together, these results implicate TZFP as a possible candidate gene 
for the upregulation of the y-globin gene in MBD2-I- mice. 
Preliminary results indicated MBD2 does not bind to the y-globin promoter region 
to mediate a repressive effect. In addition, the CpG island content of the locus was 
analyzed. Only two weak CpG islands were found, but they were not located near any 
gene within the locus. To determine whether MBD2 was recruited to one of these weak 
CpG islands, ChIP was performed. No enrichment for MBD2 was seen at the island 
located between the y- and 6-globin genes (Figure 27). Furthermore, no enrichment was 
seen at the c-globin gene promoter region or at the human P-globin transcribed region. 
The same data seemed to indicate that MBD2 was bound to the GATA-2 upstream region 
similar to results seen in MEL cells (Rodriguez et al., 2005). However, the level of 
enrichment seen is not very high. The microarray data provides the opportunity to define 
a strong positive control to confirm the initial MBD2 ChIP studies. The genes up- 
regulated in MBD2-/- erythroblasts are presumably primarily regulated by MBD2. In 
addition, most genes up-regulated by MBD2 in knock-out splenocytes contains a CpG 
island (Table 12). Thus far, only one gene has been shown to be up-regulated in the 
absence of MBD2 in mice and the study was performed in Thl and Th2 lymphocytes 
(Hendrich et al., 2001). No studies have been focused on the genes regulated by MBD2 in 
erythroid cells. As a result, MBD2 recruitment to the Ugt8 CpG island was analyzed by 
real-time PCR. Ugt8 displayed the highest fold difference between MBD2-I- and 
MBD2+/+ erythroblasts in microarray analysis and was confirmed to be expressed -4- 
fold higher in MBD2-I- cells. ChIP analysis showed MBD2 to be recruited to the Ugt8 
CpG island in wild-type but not knock-out splenocytes suggesting MBD2 mediates a 
transcriptional repressive effect directly at the Ugt8 (Figure 27). This is in contrast to 
what occurs at the y-globin gene. Loss of MBD2 leads to increased transcription, but 
MBD2 does not bind directly to the y-globin promoter region to mediate the effect. The 
Ugt8 ChIP data validates the result that MBD2 does not bind to the y-globin promoter in 
addition to validating the ability of the microarray to identify genes regulated by MBD2. 
In addition, MBD2 enrichment is seen at the CpG island located 3' of the TZFP gene. As 
another control, MBD2 was not enriched at the highly expressed human P-globin gene. 
To further confirm the result .that MBD2 does not bind to the y-globin promoter 
region, ChIP was performed with an ant-MBD213 antibody. No enrichment is seen at the 
y-globin promoter while enrichment is seen at the CpG islands near the Ugt8 and TZFP 
gene (Figure 27). Thus neither MBD2 nor MBD3 are binding near the y-globin promoter. 
ChIP was also performed with an anti-MTA2 antibody. MTA2 is part of the NuRD 
complex which associates with MBD2. MTA2 is not recruited to the y-globin promoter 
but is recruited to the Ugt8 and TZFP CpG islands. 
Discussion 
Loss of MBD2 leads to expression of the normally silent fetal globin gene, y, in 
adult PYAC transgenic mice. MBD2 mediated transcriptional repression is thought to 
occur via MBD2 recruitment to methylated CpGs in the promoter region of a gene. 
MBD2 may bind as a complex or once bound recruit a protein complex to repress 
transcription via HDACs and transcriptional repressive proteins. To determine whether 
MBD2 represses the human y-globin gene in adult PYAC transgenic mice, ChIP assays 
were.performed to determine whether MBD2 binds to the y-promoter region in vivo. No 
enrichment was found for MBD2 at the y-globin promoter region in wild-type or MBD2 
null splenocytes using two different antibodies. However, MBD2 is enriched in wild- 
type, but not knock-out, splenocytes at the GATA2 upstream promoter, the Ugt8 CpG 
island, and the CpG island 3' of the TZFP gene. This result is not surprising despite the 
high level of CpG methylation in adult erythroblasts. The y-globin gene does not contain 
a CpG island. While MBD2 can bind to as few as 3 CpGs in vitro, this has not been 
shown in vivo nor has it been shown whether MBD2 can bind as a complex to a region 
with low CpG density. MBD2 binding has been shown to increase with increasing CpG 
density (Kransdorf and Ginder, 2004). The MBD2 containing complex, MeCP1, is able to 
bind sparsely methylated DNA but it is unstable and its repressive properties can be 
overcome by a strong enhancer, similar to the LCR (Boyes and Bird, 1992). Taken 
together, it is not surprising that MBD2 mediated transcriptional repression of the y- 
globin gene is not due to MBD2 recruitment to the y-globin promoter region. 
Studies have shown that mechanisms other than simple cis element trans factor 
binding to the y-promoter exists for y-globin gene regulation. We postulated that MBD2 
mediated y-globin gene silencing may be due to up-regulation of a factor that binds to the 
y-promoter region or a factor involved in a signaling pathway needed for y-globin 
activation. As a result, we performed a microarray analysis of erythroblasts from four 
MBD2+/+ and four MBD2-I- mice. No erythroid specific factors were identified on the 
initial highly significant (p<0.005) gene list generated by microarray analysis. However, 
after analyzing the gene lists through the Ingenuity Pathway Analysis program, several 
genes involved in hematologic pathways were identified. One of these genes, TZFP, was 
found to be >20-fold enriched in MBD2-I- erythroid cells. This protein appears to be a 
potential candidate for MBD2 mediated y-repression. This protein has been shown to 
interact with GATA-2, but its effect on GATA-2 activity has not been determined 
(Tsuzuki and Enver, 2002). Overexpression of Gata-2 in K562 cells leads to increased 
expression of the y-globin gene (Ikonomi et al., 2000). TZFP may interact with Gata-2 to 
promote y-globin gene expression, however further experiments must be performed to 
prove or disprove this hypothesis. Interestingly, the TZFP gene does not contain a CpG 
island in its 5' promoter region, but does contain a CpG island 3' of the coding sequence, 
but 5' of the downstream MLL2 gene. We have shown MBD2 is recruited to this island. 
Given the large induction of TZFP expression in the absence of MBD2, this CpG island 
may be mediating a novel 3' repressive effect on TZFP. 
The results described here show the importance of validating candidate genes 
acquired from niicroarray analysis. Three genes considered to be potential candidates did 
not show a difference of expression between wild type and MBD2 knock-out 
erythroblasts: MAPK3, JunD1, and Baf57. These genes were also located in hematologic 
pathways. Given that these genes were not validated, but TZFP was validated provides 
further evidence that TZFP may be involved in MBD2 mediated y-globin repression. 
The results of the microarray analysis provided the opportunity to search for 
potential positive controls for MBD2 ChIP analysis in mouse erythroblasts. Previously, 
MBD2 had only been shown to be recruited to the IL-4 locus in mouse Thl and Th2 cells 
(Hendrich et al., 2001). No previous work has shown in vivo occupancy of MBD2 in 
erythroid cells. Interestingly, the IL-4 gene was not detected in the microarray analysis 
likely owing the lymphoid-specific factors being necessary for its expression. However, 
microarray analysis and real-time PCR indicate the gene Ugt8 is up-regulated in MBD2- 
1- erythroid cells. Furthermore, ChIP experiments show this gene to be enriched at the 
b 
CpG island region of the Ugt8 gene thus establishing a positive control. This result 
confirmed that MBD2 does not bind directly to the y-globin promoter region to mediate 
transcriptional repression. Thus, it is highly likely MBD2 is negatively regulating a gene 
in trans that when activated results in expression of the normally silent y-globin gene, for 
example TZFP. 
The mice used in this analysis were bred on a heterologous background. As a 
result, the results shown here may result in false negatives due to background modifiers. 
Thus, the gene responsible for the up-regulation of the y-globin gene may not be found 
using this technique with these samples. False positives would likely be eliminated by 
multiple repetitions in different progeny. In addition, the spleens used in this study are 
highly erythroid in composition, but are not 100% erythroid. It is possible the genes 
analyzed are from lymphoid cells and that induction of these genes in erythroid cells may 
have no bearing on y-globin gene expression. However, we hypothesized the effect seen 
may be'due to secretion of a cytokine or some other factor from a non-erythroid cells to 
mediate up-regulation of the y-globin gene. A final factor to consider in the microarray 
analysis is that erythroid cells are present at all stages of differentiation in the anemic 
spleen. The gene responsible for the phenotype may only be differentially regulated at a 
distinct stage of erythroid maturation. If this is the case, the gene will likely be difficult to 
identify amidst other erythroid cells and lymphoid cells which compromise the anemic 
spleen. To eliminate these variables, the MBD2-I- and MBD2+/+ mice must be bred into 
the same genetic background and the microarray repeated. In addition, it may prove 
necessary to isolate erythroid cells and erythroid cells from specific stages of 
differentiation from the contaminating lymphoid cells to correctly identify candidate 
genes. However, overexpression of candidate genes in MEL cells containing human 
chromosome 11 or m A C  transgenic mice would allow one to assess the effect of the 
candidate gene(s) on y-globin gene expression. These initial microarray studies have 
provided a dearth of information, but care must be taken when identifying candidate 
genes to incorporate all possible modifying variables. 
Lastly, MBD2 may be regulating a gene that results in increased levels of y-globin 
by a mechanism other than via increased transcription. For example, a protein that 
stabilizes y-globin mRNA or increases its export from the nucleus may account for the 
increased levels of y-globin mRNA. However, unless these factors are specific for the y- 
globin gene, more genes should have been up-regu1ated.h the microarray analysis. 
Lastly, the increased enrichment of TriMeK4 in MBD2 null PYAC transgenic mice 
suggest the mechanism is transcriptionally related. 
Chapter 5: Loss of MBD2 in other Erythroid Models 
Introduction 
We have shown that loss of MBD2 leads to expression of the y-globin gene in two 
lines of adult PYAC transgenic mice. The lack of a severe phenotype in MBD2-I- mice 
makes this protein a potential target for therapeutic induction of the y-globin gene for 
patients suffering hemoglobinopathies (Hendrich et al., 2001). In addition, MBD2 has 
been shown to inhibit tumor suppressors in cancer; therefore, compounds inhibiting 
MBD2 activity may have potential benefits to cancer patients (Magdinier and Wolffe, 
2001). However, loss of MBD2 must be shown to induce y-globin in other systems to 
show the effect seen in transgenic mice is conserved and thus a viable target to pursue. 
A cell culture model would be an ideal system to study this effect. Cell culture has 
the advantage of generating large amounts of material to analyze in a relatively short 
period of time. In addition, generation of transgenic cells lines is much more rapid than 
generation of transgenic mice. For analysis of potential candidate genes generated from 
microarray studies, a cell culture model has the benefit of allowing relatively rapid 
analysis of gene overexpression or knock-down using siRNA. To this end, we are using 
the mouse erythroleukemia (MEL) cell line. MEL cells are virally transformed cells 
maintained at the proerythroblast stage of differentiation. However, upon chemical 
treatment, these cells can be terminally differentiated into adult erythroid cells. Upon 
induction, these cells express high levels of adult globin transcripts. These cells provide a 
cell culture model with which to study the endogenous mouse globin genes in adult 
definitive cells. In addition, these cells have been used to study embryonic and fetal 
regulatory elements (Wandersee et al., 1996). MEL cells have also been created that 
contain the entire human chromosome 11 by using cell fusion (Forrester et al., 1990). 
These cells mimic adult erythroid cells in that they predominantly express the P-globin 
gene. MEL cells containing human chromosome 11 express the y-globin upon treatment 
with 5-azacytidine (Ley et al., 1984). Thus, MEL cells containing human chromosome 11 
(N-MEL) behave similarly to m A C  transgenic mice and human patients. 
Another model system employed is the differentiation of human hematopoietic 
stems cells (HSC) down the erythroid pathway. Human HSCs express high levels of the 
glycoprotein CD34. As these cells differentiate they lose expression the CD34 surface 
marker. CD34+ cells are capable of initiating long-term hematopoiesis both in vitro and 
in vivo. CD34+ cells can be found in bone marrow, mobilized peripheral blood, cord 
blood, and the fetal liver. When grown in the right mixture of chemicals and cytokines, 
these cells can differentiate into cells of any hematopoietic lineage. Numerous studies 
have demonstrated methods for differentiation of CD34+ cells down the erythroid 
pathway (Bhanu et al., 2004; Fibach et al., 2003; Migliaccio et al., 2002). This system has 
the benefit of using human cells. However, these cells are not immortal and selection of 
transfected constructs is difficult to accomplish. Thus, to insert foreign DNA sequences 
these cells must be infected with viruses carrying the DNA of interest. Lentiviruses have 
been used to successfully transduce human CD34+ cells (Gimeno et al., 2004). 
The goal of these model systems is to first recapitulate the effect seen in PYAC 
transgenic mice in a cell culture system. The reason for this is two-fold. First, 
demonstrating the phenotype in multiple systems suggests the effect is evolutionarily 
conserved and not unique to the PYAC model. As a result, MBD2 becomes a potential 
target for manipulating HbF levels in patients with hemoglobinopathies. Second, the cell 
culture system is much more conducive to validating potential candidate genes generated 
from microarray analysis. Validating candidate genes through gene over-expression and 
siRNA knock-down is much more efficient than generating transgenic and knock-out 
mice. Thus, additional model systems are needed for proof of principle as well as further 
dissecting the exact mechanism of MBD2 mediated y-globin transcriptional repression. 
Methods 
Culture and analysis of N-MEL cells 
N-MEL cells were a generous gift from Dr. M.A. Bender (Fred Hutchinson 
Cancer Research Center, Seattle, Washington) (Forrester et al., 1990). Cells were 
maintained in DMEM supplemented with 10% heat inactivated fetal bovine serum and 
grown at 37' C and 5% COz. The human chromosome 11 does not have a selectable 
marker and the cell eventually loses the chromosonle with culture. In order to keep a high 
percentage of N-MEL cells, the cells were periodically purified using an antibody 
directed against a cell surface marker expressed from the human chromosome, UME7. 1- 
2 x lo8 cells were spun down and resuspended in 500 pL of UME7 anti-serum. The cells 
were then incubated at room temperature for 15 minutes. The cells were washed in 15 mL 
PBS/2% FBS11 mM EDTA and spun at 1000 x G. The cells were resuspended in PBSl2% 
FBSll mM EDTA to 1-2 x108 cellslmL. FITC conjugated goat anti-mouse antibody (MP 
Biomedicals) was added to 3 pg/mL. The cells were allowed to incubate for 15 minutes at 
room temperature. The cells were washed again with 15 mL PBS/2%FBS/lmM EDTA 
and resuspended to 1-2 x 1 o8 celllmL in a 5 mL Falcon Polystyrene tube. Anti-FITC 
antibody (Stem Cell) was added at 100 pL per 1 niL of cells and allowed to react for 15 
minutes at room temperature. Magnetic nanoparticles (Stem Cell) were added at 50 pL 
per mL of cells and allowed to react for 10 minutes. After incubation, the volume was 
increased to 2.5 mL with PBS/2%FBS/1 mM EDTA and placed in an EasySep Magnet 
(Stem Cell) for 5 minutes. The supernatant was then decanted and the tube removed from 
the magnet. The cells were resuspended in 2.5 mL of PBS/2%FBS/ 1 mM EDTA and 
placed back in the magnet for 5 minutes. This process was repeated for a total of three 
magnetic purifications. After the final wash, the cells were resuspended in normal 
medium and allowed to grow. 
After purification, N-MEL cells were tested for their ability to express the human 
globin genes. Cells were treated for 3 days in the presence of 2% DMSO or not treated. 
RNA was isolated using Trizol, DNase I treated, and reverse transcribed as described 
earlier. Expression of human y-globin and P-globin transcripts was determined using real- 
time PCR. 
ChIP Assay wilh N-MEL cells 
The ChIP assay was performed essentially as described in Chapter 2 with the 
following changes. Each IP was performed with -6 x lo6 cells. 
Treatment of N-MEL cells with 5-azacytidine 
N-MEL cells were plated at a density of 3 x 1 o6 cells per 10mL medium. Cells 
were treated with 2.5 pM 5-azacytidine (Sigma) for 2 days. Every 24 hours the cells were 
spun down and replaced with fresh medium and 5-azacytidine. On the third day, the cells 
were treated with 5-azacytidine at a concentration of 9.82 pM. The cells were harvested 
48 hours later. Another set of cells was treated 24 hours after dilution with 2% DMSO. 
Another set of cells was treated with 2.5 pM 5-azacytidine for 24 hours, the cells spun 
down and resuspended in fresh medium containing 2% DMSO. Finally, a group of cells 
was left untreated. 
RNA was isolated from cells using Trizol as described earlier. The RNA was 
DNaseI treated and reverse-transcribed. Analysis of y-globin gene expression was 
determined using real-time PCR. 
Cloning a mouse MBD2 shRNA 
The sequence for mouse MBD2 mRNA (GeneBank ascension NM-0 10773) was 
analyzed using three different web-based siRNA design programs: Ambion 
(www.ambion.com), Qiagen (www.qiagen.com), and IDT DNA Technologies 
(www.idtdna.com). Three siRNAs present in all three analyses were used. To generate a 
shRNA expressing vectors, the siRNAs from the analyses were fitted with a loop 
sequence and compatible ends for cloning into the EcoRI and XbaI site of the psuperior 
vector. The psuperior vector was cut with EcoRI and XbaI at 37" C for 2 hours followed 
by heat inactivation of the enzymes at 65" C for 20 minutes. The cut plasmid was gel 
purified on a I % agarose gel using the Qiagen gel extraction kit (Qiagen). Oligos 
corresponding to the three siRNAs of interest were ordered as oligos from IDT DNA 
Technologies. The oligos were ordered as top and bottom strand and left and right half. 
The top and bottom of each half were phosphorylated with T4 polynucleotide kinase at 
37" C for 40 minutes. The enzyme was inactivated by heating at 65" C for 15 minutes. 
The oligos were annealed by boiling for 5 minutes followed by gradual cooling to room 
temperature to make a dsDNA at 5 pmol/pL. The ligation was performed in two steps. 
First, 1 pL of the left half dsDNA was added to 36 ng of cut and purified psuperior. The 
fragments were ligated with T4 ligase in a volume of 20 pL at room temperature for 3 
hours. Afterwards, 1 pL of pellet paint (Novagen) was added and the DNA ethanol 
precipitated at -20" C for 30 minutes. The DNA was spun and the pellet washed in 70% 
ethanol. The pellet was resuspended in 20.5 pL water. The second ligation was performed 
by adding 1 pL of the right dsDNA and T4 ligase in a volume of 25 pL at room 
temperature for 2 hours. Alpha-Select Bronze Efficiency cells (Bioline) were transformed 
with 5 pL of ligation product. Colonies were screened for clones containing the insert. 
Positive clones were then sequenced to confirm the presence and sequence of the insert. 
The list of oligos used for cloning is located in Table 13. The cloned siRNAs were 
labeled as pSuperior30,45, and 95. 
Oligo Name Sequence 
GATCCTGAACAACCACGTCAGCTT 
CTCTTGAAAAGCTGACGTGGTTGTTCAG 
TTCAAGAGAAAGCTGACGTGGTTGTTCATTTTTTC 
TCGAGAAAAAATGAACAACCACGTCAGCTTT 
GATCCAGGTAGCACTTACGTGAAA 
CTCTTGAATTTCACGTAAGTGCTACCTG 
TTCAAGAGATTTCACGTAAGTGCTACCTTTTTTTC 
TCGAGAAAAAAAGGTAGCACTTACGTGAAAT 
GATCCGGGTAAACCAGACCTGAAC 
CTCTTGAAGTTCAGGTCTGGTTTACCCG 
TTCAAGAGAGTTCAGGTCTGGTTTACCCTTTTTTC 
TCGAGAAAAAAGGGTAAACCASGACCTGAACT 
Table 13: Oligos used to generate M B D ~  shRNA constructs. 
Transfection of shRNA constructs into N-MEL Cells 
Each siRNA vector (4.5 pg) was diluted to 250 pL with Opti-Mem (Invitrogen) 
and lightly vortexed. Lipofectamine 2000 (10 pL) (Invitrogen) was diluted to 250 pL in 
Opti-Mem, vortexed lightly, and incubated at room temperature for 5 minutes. The DNA 
mixture and Lipofectamine mixture were combined, vortexed gently and incubated at 
room temperature for 20 minutes. This mixture was then added to 2 mL of magnetically 
purified N-MEL cells and grown overnight at 37' C in 5% C02. After 24 hours, the cells 
were split and diluted 1 : 10 (final volume 5 mL) in DMEM and grown for 24 hours at 37' 
C in 5% C02.  48 hours after transfection, G418 (Invitrogen) was added to the medium at 
1 mg/mL to select for transfected cells. After selection, a pool of transfected cells was 
generated. From this pool, single cell colonies were grown. These single cell clones were 
screened for expression of MBD2 by real-time PCR and Western Blot. The list of primers 
used for real-time PCR to assay for transcript level is located in Table 14. 
Western Blot 
Nuclear extracts were prepared by the Dignam method (Dignam et al., 1983). 
Protein samples were run on 10% Tris-glycine SDS-PAGE ReadyGels (Bio-Rad) in 
Running buffer (25 mM Tris-HC1 pH 8.3, 192 mM glycine, 0.1 % SDS). The gel was 
equilibrated in Transfer buffer (25 mM Tris-HC1 pH 8.0, 192 mM glycine, 20% 
methanol) and then transferred to activated PVDF overnight at 30V. The next day the 
membrane was washed twice for 10 minutes with l x  PBS and .then blocked for 1 hour at 
room temperature with rocking in 10 mL MPBST (5% (wlv) non-fat milk, l x  PBS, 
Primer Sequence 
mMBD2-1757-F-73 TTTATAATAGCAAGCAGGGCCCTTCCGGTG 
mMBD2- 1757-R-2 15 
mMBD2- 106 1 -F-49 
mMBD2- 106 1 -R- 157 
mMBD2-93 8-F- 1 5 
mMBD2-93 8-R- 129 
GGGAAACTTATTTGGTACTCCTGATCTGT 
CAAATTCACGAACCACCCGAGCAA 
TGATGCGCTAAGTCCTTGTAGCCT 
TTGACTTCAGGACCGGCAAGATGA 
GGCAATGTTGTGTTCAGGTCTGGT 
Table 13: Primers used to analyzed transcript levels in N-MEL cells transfected with 
MBD2 shRNA vector. 
0.05% Tween-20). The blocking solution was removed and the primary antibody, anti- 
MBD2 (Upstate) was incubated with the membrane at 3 pg/mL for 2 hours at room 
temperature with rocking in MPBST. This solution was removed and the membrane 
washed three times with 10 mL PBS-T for 5 minutes. The secondary antibody was then 
incubated with the membrane for 1 hour at room temperature with rocking in MPBST. 
This solution was removed and the membrane was washed three times with 10 mL PBS- 
T for 5 minutes and one time with 10 mL PBS-T plus 0.1 % Triton-X 100. Bands were 
visualized with ECL Plus (Arnersham Phannacia) and exposed to film. The blot was 
stripped by incubating in 100 mM 2-mercaptoethanol, 2%SDS, and 62.5 mM Tris-HC1 
ph 6.7 at 50" C for 30 minutes. The blot was washed in PBST and re-probed as above 
using an anti-pactin antibody (Sigma). 
Isolation and Differentiation of human CD34+ Cells 
CD34+ cells were isolated from two sources: cord blood and aphaeresis pack. 
Aphaeresis packs were obtained from the VCU Bone Marrow Transplant Lab. The pack 
was thawed at 37" C until it became slushy, at which time thawing was completed at 
room temperature. Cord blood was obtained from the VCU department of Obstetrics and 
used within 24 hours of collection. The cells were diluted with an equal volume of 
PBS/2% FBS. 30 mL of cells was loaded onto 15 mL of Ficoll Paque Plus (Stem Cell) 
and spun at 400 x G for 30 minutes with no brake. The middle mononuclear layer was 
extracted, diluted to 40 mL with PBS/2%FBS/1 mM EDTA and filter through a 70 pM 
nylon filter (BD Biosciences). The cells were counted, washed twice in PBS/2%FBS/l 
mM EDTA, and diluted to 4 ,x 10' cell1mL in a 5 mL Falcon Polystyrene tube. Human 
CD34+ positive selection cocktail (Stem Cell) was added at 100 pL per mL of cells and 
allowed to incubate for 15 minutes at room temperature. Magnetic nanoparticles were 
then added at 50 pL per mL of cells and allowed to react at room temperature for 10 
minutes. The cells were then magnetically purified as described above except the cells 
were washed 4 times. The cells were resuspended at -1 x lo6 cells per mL in 
amplification medium: IMDM, 20% FBS, 10 ngImL Stem Cell Factor (R&D Systems), 1 
UImL EPO (Arngen), 1 mgImL IL-3 (R&D Systems), 1 o - ~  M dexamethasone (Sigma), 
and M estradiol (Sigma). Cells were grown for two weeks and maintained at 1 x lo6 
cells per mL. After two weeks, cells were spun down and washed 1X with IMDM 
medium and resuspended in differentiation medium: IMDM, 20% FBS, 1 UImL EPO, 
and 10 ng/mL insulin (Sigma). The cells were allowed to differentiation for 5 days. After 
differentiation, cells were spun down and RNA isolated using Trizol. The presence of 
globin gene transcripts was determined using RNase protection assay. 
Results 
The N-MEL cell line does not possess a selectable marker. As a result, the cell is 
prone to losing the human chromosome 11 with prolonged culture. We first had to ensure 
we could maintain the cell line in culture, purify it, and determine if it was expressing the 
0-globin gene. Cells were successfully grown-up in culture and MEL cells containing 
chromosome 1 1 were enriched using an anti-serum against a chromosome 1 1 marker and 
magnetic beads. After purification, cells were grown in culture and differentiated down 
the erythoid pathway with DMSO. After three days of differentiation, RNA was isolated 
and analyzed by RT-PCR. As shown in Figure 30, the N-MEL cells were actively 
expressing the human 6-globin gene. A sub-set of purified cells were amplified in culture 
to generate enough cells for ChIP assay. To ensure we could successfully use the N-MEL 
cell line for ChIP assays, we performed a ChIP assay for TriMeK4 at the human 6-globin 
locus. As shown in Figure 3 1, the human 6-globin gene is highly enriched for TriMeK4, 
indicating successful application of the N-MEL cell line. In addition, the y-globin gene is 
not enriched in these cells, consistent with low levels of expression (Figure 3 1). 
Activation of the y-globin gene has been shown in MEL cells containing human 
chromosome 11 (Ley et al., 1984). However, it is not known whether the N-MEL cells 
used here express the y-globin gene after 5-azacytidine treatment. N-MEL cells were 
treated with 5-azacytidine and showed a -10-fold induction in y-globin expression as 
determined by real-time PCR (Figure 32). This level of induction is similar to the level 
seen after treating PYAC transgenic mice with 5-azacytidine or when MBD2 has been 
genetically deleted in PYAC transgenic mice. However, treatment for 24 hours prior to 
DMSO induction was unable to induce expression, but was shown to induce expression 
in a different MEL human chromosome 1 1-containing cell line (Ley et al., 1984). 
However, the amount of time the cells were allowed to induce and the inducing agent 
, 
differed in these studies and may account for the variations in expression. The N-MEL 
cells here were harvested four days after 5-azacytidine treatment, which may be enough 
time for the cells to recover from the demethylating effects of the compound. 
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Figure 30: Expression of the human 0-globin gene in N-MEL cells after magnetic 
purification. N-MEL cells were purified magnetically using an anti-serum against a 
chromosome 11 marker and magnetic beads. The purified cells were differentiation down 
the erythroid pathway with DMSO and RNA analyzed using RT-PCR. Shown above are 
the results of the RT-PCR analysis. 
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Figure 3 1 : ChIP assay with magnetically purified N-MEL cells at the human 6-globin 
gene. After magnetic purification, N-MEL cells were amplified and subjected to ChIP 
assay with an anti-body directed against TriMeK4 and IgG. DNA was analyzed using 
real-time PCR at the human 6-globin gene and the endogenous amylase gene. 
Figure 32: y-globin expression in N-MEL cells after 5-azacytidine treatment. N-MEL 
cells were treated with 5-azacytidine either with or without DMSO. Expression of the y- 
globin gene was performed by real-time PCR relative to the GlycophorinA gene. 
After establishing we could enrich for N-MEL cells after prolonged culture, we 
sought to transfect these cells with a vector expressing a siFWA against mouse MBD2. 
Three web-based design programs were used to identify potential siRNA sequences. 
Three regions were found in all three programs and siRNA constructs were generated for 
these regions and cloned into the psuperior vector. N-MEL cells enriched by magnetic 
purification were transfected with all three constructs and grown in medium containing a 
selection agent. After isolating a pool of transfected cells, single cell clones were isolated 
and screened for MBD2 expression levels by Western blot and real-time PCR. As shown 
in Figure 33, multiple clones had >90% knock-down of MBD2, while others showed 
minimal knock-down. Clone 45, which showed the greatest level of MBD2 knock-down, 
was selected for further studies. 
Another model system we wished to employ for the study of MBD2 mediated 
transcriptional repression of the y-globin gene is the human CD34+ differentiation model. 
In this system, CD34+ cells isolated from human aphaeresis packs are forced down the 
erythroid pathway using a cocktail of cytokines favoring this pathway. A goal we set for 
this system was for y-globin expression to be very low at the end of culture (<2% of 
human 6-globin). To compare expression levels, adult and cord blood CD34+ cells were 
used. After isolation and differentiation of CD34+ cells, RNA was isolated and analyzed 
by W A .  As shown in Figure 34, erythroid differentiated CD34+ cells isolated from 
adults express high levels of 6-globin mRNA and low levels of y-globin mFWA. Thus, 
this culture system expresses low enough levels of y-globin that loss of MBD2 should 
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Figure 33: Western blot (Top) and real-time PCR (Bottom) analysis of N-MEL clones 
contain a MBD2 shRNA vector. After transfection and selection, N-MEL cells contain a 
MBD2 shRNA vector were grown as single cell clones. Individual clones were screened 
for expression of MBD2 by Western blot and real-time PCR. 
Figure 34: RPA analysis of y-globin expression levels in erythroid differentiated CD34-t 
cells obtained from adult and cord blood. CD34+ cells were isolated and differentiated 
down the erythroid pathway. After differentiation, levels of y- and P-globin niRNA were 
determined by RPA. 
produce a measurable increase in expression. As expected, CD34-t cells isolated from 
cord blood express high levels of y-globin after erythroid differentiation. 
Discussion 
Here we have shown the characterization of two model systems with which to 
study MBD2 mediated transcriptional repression of the y-globin gene. The first system is 
a mouse erythroleukemia cell line containing human chromosome 1 1. The chromosome 
has no selectable marker and the cells have a tendency to expel the foreign DNA after 
prolonged passage. We first needed to ensure these cells could be purified and maintained 
in culture. Using a magnetic purification system, N-MEL cells were specifically enriched 
and were shown to express high levels of the human P-globin gene. Next, we wanted to 
determine whether N-MEL cells could be ChIPed using our protocol and whether they 
behaved similar to adult m A C  erythroid cells. The results of the ChIP assay 
demonstrated that the P-globin gene region was highly enriched while the y-globin gene 
was not enriched for histone H3 trimethylated at lysine 4. This result was consistent with 
the results seen in the wild type PYAC transgenic mice as well as with the levels of 
expression of these two genes in N-MEL cells. Additionally, N-MEL cells were treated 
with 5-azacytidine to determine whether or not the y-globin gene could be induced. 
Consistent with the previous data in another MEL cell line containing human 
chromosome 11, 5-azacytidine led to a -10-fold induction the of the y-globin gene, a 
level of induction similar to PYAC mice treated with 5-azacytidine (Ley et al., 1984). 
However, pre-treatment with 5-azacytidine followed by DMSO induction was unable to 
induce expression. However, these cells were harvested four days following 5- 
azacytidine treatment. This may have been enough time for effects of demethylation to be 
reversed, or 24 hours of treatment may not be long enough to induce y-globin expression 
in N-MEL cells. 
Taken together, these results indicate that N-MEL cells may be a good model 
system in which to study MBD2 mediated repression of the y-globin gene. These cells 
appear to behave very similarly to adult m A C  erythroid cells. As a result, N-MEL cells 
were transfected with a construct generating a siRNA against murine MBD2. Analysis of 
these cells identified multiples sub-lines with >90% knock-down of MBD2 mRNA and 
protein levels. Due to the long selection time following siRNA transfection, the pool 
likely has lost chromosome 11 in many cells. As a result, the cells were grown and 
magnetically purified. Hemizygous MBD2 m A C  transgenic mice do not show any 
significant increase in y-globin expression relative to wild-type mice. Thus, we postulated 
that it would take nearly 100% knock-down of MBD2 to mirror the phenotype seen in 
MBD2 null transgenic mice. These cells have a dramatic knock-down of MBD2 and 
should express the y-globin gene if the effect is cell autonomous. 
Since N-MEL cells appear to accurately mimic adult PYAC erythroid cells, this 
system will be very useful for testing candidate y-globin regulators determined from 
microarray analysis. We have shown that these cells can be transfected and can knock- 
down gene expression using siRNA. As a result, these cells can be used to test candidate 
genes. For example, adult MBD2-1- erythroid cells express a high level of TZFP. An 
expression plasmid can be used to over-express this gene in N-MEL cells to determine 
whether it induces y-globin expression. The converse also applies to genes down- 
regulated in the absence of MBD2; siRNA vectors to these genes can be generated and 
used to knock-down the gene to determine whether the y-globin gene is up-regulated. 
Overall, the N-MEL system has the potential to be a very valuable and powerful system 
with which to study MBD2-mediated transcriptional repression of the y-globin gene. 
The other model system explored here was the erythroid differentiation of human 
CD34+ cells. We have shown successful differentiation of adult and cord blood derived 
CD34+ cells down the erythroid pathway. In addition, we needed to ensure the level of y- 
globin expression in adult derived erythroid cells was low. Given the high level of 
transcription of the 0-globin gene, there may be a level of y-globin expression that cannot 
be exceeded without first down-regulating ,6-globin expression. The main goal of this 
model system is to determine whether MBD2 knock-down results in increased y-globin 
expression in a human model system. If this can be shown, the potential exists that 
MBD2 may be a target for pharmacological induction of HbF. Thus, we needed to 
determine .the level of y-globin expression in adult erythroid cells. There was no 
detectable y-globin expression in adult erythroid differentiated CD34+ as determined by 
RNase protection assay. This result indicates that if MBD2 is playing a similar role in 
human cells, knock-down of the gene may lead to a detectable increase in y-globin 
expression. Now that y-globin levels have been shown to be barely detectable, the next 
step is to transduce CD34+ with an MBD2 siRNA followed by differentiation and globin 
expression analysis. 
Chapter 6: Summary and Future Directions 
The genes of the human 6-globin locus undergo a switch in expression during 
development. During this sequential process, the 5' gene in the cluster is silenced while 
the immediate 3' gene(s) becomes active. Thus, the genes are expressed in the order in 
which they lie on chromosome 11: 5' 6 ,  y, and 6 3'. The silencing and activation of the 6- 
type globin genes involves conserved mechanisms in addition to unique mechanisms for 
each gene. For example, each gene requires the LCR for high level expression. On the 
other hand, the 0-globin gene requires the transcription factor EKLF while the E -  and y- 
globin do not require it for expression (Nuez et al., 1995; Perkins et al., 1995). The exact 
mechanism for globin gene switching is not fully understood, but it has been shown to 
involve many interdependent processes including cis elements, trans factors including 
tissue specific factors, developmental specific factors and ubiquitous factors, and 
epigenetics. Our lab has a particular interest in the latter mechanism, epigenetics. 
Epigenetic mechanisms result in heritable changes in gene transcription that do 
not alter DNA sequence. A prototypical epigenetic modification is the addition of a 
methyl group to the 5' position of cytosine in the context of the CpG dinucleotide. 
Increased levels of DNA methylation are associated wi.th decreased transcription, a 
correlation first noted in the P-globin locus (McGhee and Ginder, 1979). Since that time, 
DNA methylation has been shown to play a part in P-type globin gene regulation in many 
different model systems and inhibition of DNA methylation by the con~pound 5- 
azacytidine has been shown to activate silenced globin genes in model systems and 
patients with hemoglobinopathies (Atweh et al., 2003; Charache et al., 1983; DeSimone 
et al., 1982; Ginder et al., 1984; Ley et al., 1982; Ley et al., 1983; Ley et al., 1984; Pace 
et al., 1994; Zucker et al., 1983). The mechanism by which DNA methylation mediates 
transcriptional silencing was fostered by the discovery of a family of proteins that 
specifically bind to methylated DNA. Furthermore, the proteins were shown to bind as 
large complexes containing transcriptional repressive proteins. One such protein, MBD2 
was shown to bind to a methylated p-globin construct as part of a large complex (Singal 
et al., 1997; Singal et al., 2002). This complex was further purified from primary 
erythrocytes and shown to contain MBD2. Finally, MBD2 was shown to bind to the p- 
globin proximal transcribed CpG islands in vivo (Kransdorf and Ginder, 2004). 
We sought to determine the impact MBD2 on the regulation of the human 
embryonic and fetal globin genes. Mice transgenic for different human @-type globin 
constructs were utilized as a model system. Mice containing the entire P-globin locus as a 
yeast artificial chromosome were the model system used to study regulation of the y- 
globin gene. Similar to results published with a different line of PYAC transgenic mice, 
we observed activation of the y-globin gene in adult mice upon treatment with the 
compound 5-azacytidine (Pace et al., 1994). DNA methylation and MBD2 have been 
shown to, in part, mediate the silencing of the avian embryonic p-globin gene (Ginder et 
al., 1984; Singal et al., 1997; Singal et al., 2002). PYAC transgenic mice were bred with 
mice null for MBD2 to generate transgenic knock-out mice. Adult PYAC transgenic mice 
lacking functional MBD2 express mRNA from the normally quiescent y-globin gene. 
Loss of MBD2 leads to a 10-20 fold induction of y-globin mRNA in two different PYAC 
transgenic mouse lines. This effect appears to be very specific as PYAC mice 
hemizygous and homozygous for MeCP2, another MCBP, do not show the same effect. 
Furthermore, the endogenous embryonic mouse globin transcripts are not increased in the 
absence of MBD2. The impact of MBD2 loss on y-globin expression is not only seen in 
adult mice, but also during development. Embryos null for MBD2 at 14.5dpc and 
16.5dpc express the y-globin gene at higher levels than wild-type embryos. MBD2 is 
needed to maintain y-globin gene repression in adult mice and is necessary for 
developmental silencing. The increased expression of the y-globin gene in adult mice is 
due to expression of the gene during definitive erythropoiesis rather than a reactivation of 
A A  G embryonic erythropoiesis as the level of y/ yt y is consistent with the ratio seen in adult 
human F-cells. 
It is hypothesized that epigenetic modifications beget other epigenetic 
modifications to impart transcriptional silencing. For example, it has been shown .that loss 
of a histone methyltransferase leads to decreased levels of DNA methylation (Tanlaru 
and Selker, 2001). To determine precisely how MBD2 mediated a repressive effect on y- 
globin transcription, we first looked for changes in DNA methylation around the y-globin 
promoter. In adult mice, the y-globin promoter and proximal transcribed region are highly 
methylated while treatment with 5-azacytidine leads to -50% decrease in DNA 
methylation levels and a concomitant increase in y-globin transcription. If MBD2 binding 
to the y-globin promoter region results in subsequent recruitment of DNMT, DNA 
methylation levels should be significantly decreased around the y-globin promoter in the 
absence of MBD2. However, DNA methylation levels around the y-globin promoter are 
only modestly decreased to -75% of wild-type levels in MBD2 null mice. Thus it seems 
unlikely MBD2 is recruiting DNMT to the y-globin promoter region and more likely that 
instead the modest decrease in DNA methylation around the y-globin promoter is due to 
increased transcription of the gene. We next determined what impact loss of MBD2 has 
on post-translational histone modifications around the y-globin gene. Not surprisingly, 
histone H3 trimethylated on lysine 4 was enriched -4-fold in knock-out mice versus 
wild-type mice. This modification is associated with active transcription, indicating the 
increase in y-globin expression is due to increased transcription of the gene. On the other 
hand, no significant difference was seen in the levels of acetylated histones H3 and H4 
between wild-type and knock-out mice. These data indicate that MBD2 is not recruiting 
HDACs to the y-globin gene region due to the lack of increase in enrichment of 
acetylated histones H3 and H4 in MBD2 null mice. Adult MBD2 null OYAC transgenic 
mice and D A C  mice treated with 5-azacytidine express the y-globin gene at similar 
levels. To determine whether MBD2 and 5-azacytidine function in the same pathway(s), 
MBD2 null and wild-type PYAC transgenic mice were treated with 5-azacytidine to 
compare levels of induction of the y-globin gene relative to pre-treatment levels. The 
nominal additive induction of the y-globin gene in MBD2 null mice treated with 5- 
azacytidine suggests that both MBD2 and 5-azacytidine are working chiefly along the 
same pathway(s). 
We next explored the role of DNA methylation and MBD2 on the regulation of 
the embryonic e-globin gene. To study human e-globin regulation, transgenic mice 
containing the entire sequence from 5' of HS5 through 4 and 12kb 3' of the e-globin 
polyA site were generated. Similar to results with other human e-globin gene transgenic 
mice, these mice show correct developmental silencing of the transgene during 
development: high expression in the 10.5 dpc yolk sac and low to no expression in the 
14.5 dpc fetal liver and adult erythroid cells. Three lines were used in the studies: two 
28kb lines and one 36kb line. Adult mice from all three lines effectively express the 
normally silenced transgene upon a 5-day treatment course with 5-azacytidine. 28kb 
LCRe transgenic mice show high levels of DNA methylation around the promoter and 
proximal transcribed region in adult erythroblasts (>go%) and low levels of DNA 
methylation in 10.5dpc yolk sacs (<40%). The level in the yolk sac is likely to be even 
lower than calculated, due to contaminating epithelial cells. Treatment with 5-azacytidine 
reduces the level of DNA methylation -20%. This modest decrease in DNA methylation 
is likely a copy number effect as not all copies of the transgene may be equally 
demethylated. In contrast to the results in human e-globin construct mice, in the context 
of mice containing the entire 0-globin locus as a yeast artificial chromosome transgene, 
the e-globin gene is expressed at a much lower level upon 5-azacytidine treatment. 
Similar to the results seen with 5-azacytidine, adult 28kb LCRE lines 1 and 2 express the 
transgene when they are null for MBD2. Once again, PYAC mice do not express high 
levels of .the c-globin gene in the MBD2 null background. f l A C  mice lacking MBD2 
express the y-globin gene at a level commensurate with wild-type mice treated with 5- 
azacytidine. One line of 28kb LCRc transgenic mice expresses the c-globin gene at higher 
levels in the MBD2-I- background than upon treatment with 5-azacytidine. This result 
seems to indicate a possible position effect of the transgene rendering them more 
sensitive to changes in epigenetic status than f l A C  transgenic mice. The c-globin gene 
has been reported to be silenced by a process termed autonomous silencing whereby the 
promoter and 5' flanking region of the gene contain all elements necessary for correct 
developmental silencing in the absence of other P-type globin genes competing for 
enhancer activity (Raich et al., 1990; Shih et al., 1990). On the other hand, the y-globin 
gene has been shown to be silenced by a combination of autonomous silencing and 
competition with the P-globin gene for the enhancer activity of the LCR (Behringer et al., 
1990; Dillon and Grosveld, 1991; Enver et al., 1989; Enver et al., 1990). These results 
indicate that the c-globin gene can be activated upon 5-azacytidine treatment or in the 
MBD2-I- background, but it remains highly repressed under the same conditions when 
other globin genes are present. Therefore, it appears that a combination of 5' cis sequence 
mediated autonomous silencing, LCR competition, and DNA methylation contribute to 
maintain the lo4 level of silencing of the c-globin gene in adult erythroid cells. 
To determine the exact mechanism of DNA methylation and MBD2-mediated 
repression of the E -  and y-globin genes, ChIP assays were perfomled to determine 
whether MBD2 was bound to the promoter region of either gene. MBD2 does not 
associate with the y-globin promoter in either MBD2+/+ or MBD2-1- mice. However, 
MBD2 does associate with the Ugt8 CpG island, the upstream GATA2 promoter, and the 
CpG island 3' of the TZFP gene in MBD2+/+ but not MBD2-1- mice indicating the 
specificity of the antibody and validity of the assay. These results indicate that MBD2 
mediated transcriptional silencing of the y-globin gene is not due to the direct binding of 
MBD2 to the promoter region of the y-globin gene. MBD2 is likely repressing a gene in 
trans that when expressed induces transcription of the y-globin gene. In an effort to 
determine what gene(s) MBD2 may be regulating, a microarray analysis was performed 
on splenocytes from MBD2 wild-type and knock-out mice. The initial analysis of up- 
regulated genes failed to identify an erythroid specific transcription factor. However, 
after analyzing the data set using a pathway analysis program, a group of genes from 
known hematopoietic pathways were identified. Validation of potential candidate genes 
revealed TZFP as a candidate. The expression of this gene is increased -30-fold in 
MBD2 null erythroid cells. In addition, TZFP interacts with GATA2, a protein shown to 
increase transcription of the y-globin gene upon over expression (Ikonomi et al., 2000; 
Tsuzuki and Enver, 2002). While the nature of this interaction is not known, TZFP is 
currently a lead candidate for future analysis. 
Through the course of these studies, it was revealed that MBD2 is necessary for 
silencing the y-globin gene in adult PYAC transgenic mice and during development. The 
effect of MBD2 on y-globin is very specific, as no other embryonic globin genes are up- 
regulated in its absence nor was loss of another MCBP able to recapitulate this 
phenotype. Absence of MBD2 is associated with modest changes in DNA methylation 
and histone acetylation around the y-globin gene, but the increased level of transcription 
is associated with an increase in trimethylated histone H3 lysine 4. MBD2 is not 
mediating its repressive effect at the y-globin promoter region as MBD2 did not CliIP to 
the y-globin promoter region. The phenotype observed is likely due to MBD2 mediated 
repression of a y-globin activator(s) of which TZFP has been identified as a potential 
candidate. Taken together, we believe MBD2 is repressing a gene that when activated 
either directly or indirectly activates y- and c-globin transcription (Figure 35). Finally, 
inhibition of DNA methylation and loss of MBD2 revealed a competitive silencing 
mechanism for maintaining c-globin transcriptional repression. In the absence of other 
globin genes, loss of MBD2 and 5-azacytidine each led to expression of the c-globin gene 
in adult mice. However, these same conditions fail to induce significant expression of the 
c-globin when other @-type globin genes are present on the transgene. 
In order to fully understand how MBD2 mediates y-globin transcriptional 
repression more work must be performed. One obvious place to begin is to determine 
whether the effect seen is unique to the mouse model utilized. N-MEL cells provide an 
opportunity to determine whether the effect can be seen in a cell culture system. N-MEL 
cells are a hybrid cell line in which normal mouse erythroleukemia cells contain a copy 
of human chromosome 11. These cells have been shown to express the @-type globin 
gene in a pattern similar to that seen in adult PYAC transgenic mice: high levels of @- 
globin and low levels of y-globin mRNA (Forrester et al., 1990). N-MELs, and a similar 
cell line containing human chromosome 11 were shown to increase expression of the y- 
globin gene upon treatment with 5-azacytidine (Ley et al., 1984). Thus, this system in 
essence mimics adult PYAC erythropoiesis. Since cells in culture can be transfected with 
Unknown gene 
y - or c-globin gene 
Figure 35: Model for MBD2 mediated transcriptional repression of the human -y- and t- 
globin genes. In adult mice, MBD2 silences and unknown gene (?). In the absence of 
MBD2 or upon treatment with 5-azacytidine, this gene becomes expressed and either 
directly or indirectly activates transcription of the human y- or e-globin genes. 
constructs producing shRNA to downregulate the target genes, the phenotype can 
potentially be reproduced in another system, adding more credibility to the results 
presented here. Further proof can be provided using erythroid differentiation of human 
CD34+ cells. CD34+ cells can be cultured and induced down the erythroid pathway to 
express globin genes (Bhanu et al., 2004; Migliaccio et al., 2002). We have shown that 
CD34+ cells obtained from adult and cord blood can be differentiated into erythroid cells. 
In addition, CD34+ cells from cord blood express high levels of y-globin niRNA while 
those derived from adult blood show <2% y-globin mRNA. As a result, this system has 
the potential to study the effect of MBD2 loss in human primary cells. CD34+ cells have 
shown the ability to be transduced by lentiviral vectors encoding shRNAs (Hong et al., 
2005). In addition, a human siRNA for MBD2 has been described (Lin and Nelson, 
2003). Transducing adult CD34+ cells with a lentiviral vector containing an MBD2 
shRNA followed by erythroid differentiation would be a valuable approach to obtain data 
to strengthen the argument that MBD2 mediates y-globin transcriptional repression in a 
variety of model systems. If these data can be obtained, the potential then exists for 
MBD2 to be a target protein for therapeutic induction of fetal hemoglobin. 
MBD2 appears to be necessary, at least in part, for the developmental silencing of 
the y-globin gene. The potential exists that the effect seen in adult PYAC transgenic mice 
lacking MBD2 is due in some way to the absence of the protein during development. In 
this case, induction of y-globin by inactivation of MBD2 in adult erythroid cells may not 
be occur if MBD2 is present during development. The N-MEL system and CD34+ 
culture systems described above would help counter this argument as these cells have 
always possessed functional MBD2. However, to test this in vivo, a conditional MBD2 
knock-out must be produced. To perform this, the MBD2 gene must be surrounded by 
loxP sites so that upon activation of Cre recombinase, the gene will be removed. The 
conditional knock-out can be performed in a variety of ways. Placing a Cre-transgene 
under the control of the 0-globin gene promoter would allow removal of the gene at an 
earlier time point, however the 0-globin gene begins to be activated around the time 
primitive erythropoiesis ends and thus does not allow for adult excision of the gene. 
Placing the Cre-gene under the control of the Tet-repressor would allow for chemical 
induction of cre expression upon treatment with tetracycline. This system would allow 
for analysis of transgenic mice that possess MBD2 during development and have only 
lost the gene as adults. This mouse model would allow one to assess the importance of 
MBD2 expression during development on y-globin activation in adult mice via MBD2 
elimination. 
One theory for the activation of globin genes upon treatment with 5-azacytidine is 
that the cytotoxic nature of the drug accelerates the differentiation of an erythroid 
progenitor. Adult erythroid cells early in the differentiation pathway have been shown to 
express the y-globin gene (Stamatoyannopoulos, 2005). Along this line, MBD2 loss may 
lead to an increase in the number of erythroid progenitors or may favor erythroid 
differentiation of hematopoietic stem cells. The increased number of erythroid cells may 
overwhelm the bone marrow leading to a situation similar to the cytotoxic theory where 
early progenitors are forced to differentiate at an accelerated rate. In this case, the 
increased number of erythroid cells would cause some early differentiating cells to 
differentiate at an accelerated rate and thus still produce y-globin mRNA. To test this 
theory, colony assays can be performed to determine whether bone marrow cells from 
MBD2 null mice produce more erythroid colonies than wild-type bone marrow cells. In 
addition, it is not yet known whether the effect of MBD2 upon y-globin expression in 
adult mice is pancelluar or heterocellular. To determine this effect, an anti-fetal 
hemoglobin antibody can be used on peripheral blood cells. The cells can either be scored 
under a microscope or via flow cytometry to determine whether all cells or a subset of 
cells express the y-globin gene. 
While the initial microarray studies on MBD2+/+ and MBD2-I- mice have been 
very informative, the analysis should be repeated to accoui~t for possible confounding 
elements. First, the mice used in the study were from a mixed genetic background. As a 
result, potential modifier genes may not have been detected. To account for this problem, 
the MBD2-I- mice can be bred into a homogeneous genetic background and the results 
compared to the pilot study to identify the effects of potential modifier genes. In the 
initial studies, erythroid cells were not purified out of the cell population. While l-acetyl- 
2-phenylhydrazine treatment results in conversion of the spleen to a 3 0 %  erythroid 
organ, lymphocytes are still present (Spivak et al., 1973). We initially wanted to include 
lymphocytes in the instance that loss of MBD2 led to cytokine release from non-erythroid 
cells that induced erythroid cells to express the y-globin gene. The potential exists that 
these cells are preventing the detection of a gene involved in y-globin induction or are 
expressing a gene at a high level that may be interpreted as a y-globin activating gene. 
Thus, the microarray analysis should be repeated after purifying erythroid cells using an 
erythroid specific marker such as Ter-119. Finally, the gene(s) responsible for y-globin 
expression may only be expressed during a certain phase of erythroid differentiation. 
Lodish and colleagues have described a method for isolating murine erythroid cells at 
different stages of erythropoiesis based on expression of the cell surface markers CD71 
and Ter-119 (Socolovsky et al., 2001). Microarray analysis can be repeated on erythroid 
cells from different stages of differentiation to discern whether the factor(s) responsible 
for y-globin expression are expressed transiently during differentiation. Furthermore, 
candidate genes from the pilot microarray study, as well as the additional studies, need to 
be validated in a cell culture model (N-MEL or CD34+) or in a mouse model. If a 
candidate gene is expressed highly in MBD2 null cells, the cDNA should be over 
expressed in N-MEL cells to determine whether it is able to induce expression of the y- 
globin gene. A more ideal system, though more time-consuming and laborious, would be 
to over-express the gene in D A C  transgenic mice to deternine whether it can 
recapitulate the effect seen in MBD2 null mice. If a candidate gene is under-expressed in 
MBD2 null cells, siRNA should be performed in N-MEL or transgenic mice to determine 
whether knock-down of the gene is able'to induce expression of the y-globin gene. While 
the initial microarray study was very informative, more characterization must be 
performed to ensure the validity of the results. 
Loss of MBD2 and DNA methylation each revealed that a competitive silencing 
mechanism exists for the human €-globin gene. It should be noted that the PYAC 
transgene contains much more additional sequence both 5' and 3' relative to the 28kb 
LCRE construct used to generate transgenic mice. Thus, the possibility exists that other 
sequences within the PYAC are responsible for the observed effect on competition. To 
test this, multiple transgenic mice lines can be made. First, a line continuing the 3' 
sequence through either y-globin gene can be generated. This transgene will only differ at 
the 3' end of the gene and would reveal whether the presence of the y-globin promoter 
can suppress expression of the €-globin gene during 5-azacytidine treatment or in the 
absence of MBD2. It may be that the y-globin promoter is insufficient to maintain E- 
globin repression, thus a construct continuing 3' through the P-globin gene can be 
generated and assayed for its ability to prevent c-globin expression. These constructs also 
contain sequence that could be confounding to the results. Thus, either the y- or 0-globin 
promoter and gene could be added immediately 3' to the 28kb LCRE construct and used 
to generate transgenic mice. This construct would show that all that is needed to suppress 
the c-globin gene is an additional P-type globin gene and strengthen the argument that a 
competitive silencing mechanism exists for the €-globin gene. 
The results presented here and proposed above serve to positively impact one 
group of patients directly and another group indirectly. One current therapeutic approach 
for the treatment of hemoglobinopathies is through the pharmacological induction of fetal 
hemoglobin. While promising results have been obtained treating patients with 5 -  
azacytidine, hydroxyurea, and short chain fatty acids, many problems still exist. These 
compounds are highly toxic and not all patients respond to the therapy. In addition, most 
of these agents have to be administered intravenously. As a result, a market for better 
pharmacological inducers of fetal hemoglobin exists. The work described here has the 
potential to lead to a new class of therapeutics, those that target MBD2. We have shown 
that in the absence of MBD2, the y-globin gene is activated in adult transgenic mice. In 
addition, mice lacking functional MBD2 display only 'a mild phenotype (Hendrich et al., 
2001). Thus, targeted disruption of MBD2 through binding site interaction or co- 
repressor interaction may be less toxic than the current line of agents. At the very least, it 
has shown an additional mechanism for y-globin silencing that may be beneficial at a 
later date. Epigenetic regulation of transcription is not limited to the 0-globin locus. 
Epigenetic modifications play a role in regulating tumor suppressor genes as well as 
imprinting genes whose dysregulation can lead to disease. Thus, understanding the 
mechanism of how MBD2 mediates repression in a tissue specific manner may be 
beneficial to the study of other pathologies where epigenetics play a crucial role in 
pathogenesis. 
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